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ABSTRACT 
Chronic Obstructive Pulmonary Disease (COPD) is the 3rd leading cause of 
death in the US, and idiopathic pulmonary fibrosis (IPF), a type of Interstitial Lung 
Disease (ILD), is a fast acting, irreversible disease that leads to mortality within 
3-5 years. RNA-sequencing provides the opportunity to quantitatively examine 
the sequences of millions mRNAs, and offers the potential to gain unprecedented 
insights into the structure of chronic non-malignant lung disease transcriptome. 
By identifying changes in splicing and novel loci expression associated with 
disease, we may be able to gain a better understanding of their pathogenesis, 
identify novel disease-specific biomarkers, and find better targets for therapy.  
 
Using RNA-seq data that our group generated on 281 human lung tissue 
samples (47=Control, 131=COPD, 103=ILD), I initially defined the transcriptomic 
xiii 
landscape of lung tissue by identifying which genes were expressed in each 
tissue sample. I used a mixture model to separate genes into reliable and not 
reliable expression. Next, I employed reads that overlapped splice junctions in a 
linear model interaction term to identify disease-specific differential splicing. I 
identified alternatively spliced genes between control and disease tissues and 
validated three (PDGFA, NUMB, SCEL) of these genes with qPCR and 
nanostring (a hybridization-based barcoding technique used to quantify 
transcripts). Finally, I implemented and improved a pipeline to perform 
transcriptome assembly using Cufflinks that led to the identification of 1,855 
novel loci that did not overlap with UCSC, Vega, and Ensembl annotations. The 
loci were classified into potential coding and non-coding loci (191 and 1,664, 
respectively). Expression analysis revealed that there were 120 IPF-associated 
and 10 emphysema-associated differentially expressed (q < 0.01) novel loci.  
 
RNA-seq provides a high-resolution transcript-level view of the pulmonary 
transcriptome and its modification in lung disease. It has enabled a new 
understanding of the lung transcriptome structure because it measures not only 
the transcripts we know but also the ones we do not know. The approaches and 
improvements I have employed have identified these novel targets and make 
possible further downstream functional analysis that could identify better targets 
for therapy and lead to an even better understanding of chronic lung disease 
pathogenesis.  
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1. INTRODUCTION 
1.1. Chronic lung diseases and public health 
Chronic lung diseases affect a significant portion of the population and account 
for over hundreds of thousands of deaths a year in the United States [3,4]. At the 
same time, the incidence of chronic lung diseases are increasing annually [5,6]. 
One type of chronic lung disease, Chronic Obstructive Pulmonary Disease or 
COPD is the third leading cause of death in the USA (potentially 1 in 20 US 
deaths) [7]. In 2003, 10.7 million U.S. adults were estimated to have COPD, 
although close to 24 million adults had evidence of abnormal lung function, 
suggesting that COPD might be under-diagnosed [8]. COPD is estimated to 
affect 10% of the world’s population, and this leads to substantial public health 
costs [9]. Emphysema, a subtype of COPD, is marked by alveolar destruction 
leading to a decrease in lung function. Another type of chronic lung disease, 
Idiopathic Pulmonary Fibrosis (IPF), a type of Interstitial Lung disease (ILD), also 
restricts breathing, and is characterized by progressive scarring of the airway 
interstitium of the lung [10,11].  
 
While the majority of deaths due to chronic lung disease are due to COPD, more 
than 15,000 deaths a year are due to IPF, an aggressive and nearly always fatal 
fibrotic disease [12,13]. The incidences of idiopathic pulmonary fibrosis have also 
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doubled over the past decade and death rates continue to rise, especially among 
the elderly [14]. Despite major investments in lung research over the past two 
decades, these diseases remain major incurable public health problems that are 
increasing in prevalence, incidence, and severity. Both diseases have different 
clinical pathology, but are associated with shared environmental factors such as 
cigarette smoking and air pollution [15-18]. In spite of the shared foundation, 
these diseases are heterogeneous both in how they appear and how they 
behave within individual patients. Moreover, IPF and COPD are traditionally 
defined by objective clinical characteristics (history, physiology, radiography, and 
pathology), and thus their underlying molecular pathogenesis remains poorly 
understood. Due to this heterogeneous nature and the poor understanding of the 
molecular pathogenesis of these diseases, there is a need for utilizing newer 
large scale approaches to identify the molecular mechanisms that make up their 
underpinnings. 
 
1.2. Overview of COPD (emphysema) and ILD (IPF) 
COPD or Chronic Obstructive Pulmonary Disease is a disease that 
predominantly affects a patient’s ability to breathe and manifests itself in two 
major forms: 1) chronic bronchitis and small airway disease marked by airway 
thickening and 2) emphysema which is marked by alveolar destruction. Both 
aspects of COPD present as a decrease in lung function through spirometry [19]. 
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This decrease in lung fuction over time is  irreversible includes symptoms such 
as shortness of breath (dyspnea), chronic cough, wheezing, and chronic sputum 
production. COPD is itself an umbrella term that is most commonly used to refer 
to patients experiencing small airway disease and chronic bronchitis, patients 
experiencing emphysema (alveolar destruction), or a heterogeneous mixture of 
these diseases [20]. It is currently projected to affect more than 10% of the world 
population and plays a significant role in more developed countries [9], and, as 
an example, it became the 3rd leading cause of death in the USA in 2008 [7, 21]. 
 
COPD has traditionally been defined by objective clinical characteristics including 
forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), the 
maximum a patient can exhale is measured, and the ratio of FEV1/FVC through 
spirometry and the GOLD staging process (GOLD stages 0 through 4) [22,23]. 
Although these classification methods have led to substantial advances in 
understanding the clinical expression of COPD, this approach has fallen short of 
being able to predict how the disease will express itself within a single patient or 
what particular treatment would have the most benefits for the individual.  
 
COPD in developed countries is associated with tobacco exposure in at least 3 
out of 4 cases [24]. While smoking is the most common contributing risk factor in 
the development and progression of COPD, the specific COPD-promoting 
processes associated with smoking are poorly understood, and the way the 
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disease progresses within an individual can vary considerably. For example, a 
similar decrease in lung function between two patients can occur and bed 
identified clinically as COPD, yet the histopathology of each individual could be 
different. One patient could show mild or almost no emphysematous destruction 
and instead have a thickening of the airway related to Chronic Bronchitis, 
whereas the other could have mostly emphysematous destruction which leads to 
their decrease in lung function. The degree and progression of airway thickening 
and emphysematous destruction varies between patients [25]. Another major risk 
factor related to COPD is age. Many of the inflammation genes and loss of lung 
function genes are themselves related to aging pathways [26]. Other factors that 
could play roles in the development of COPD include degree of smoking (such as 
pack years), environmental stresses (such as air pollution, cadmium, and diesel 
fumes [27,28]), and sex [9]. COPD pathogenesis may also be an example of 
defective repair processes or aberrant wound healing occurring in the lung and 
this could explain some of the patient to patient variability [29] . 
 
ILD or Interstitial Lung Disease is an umbrella term that covers a large number of 
irreversible lung diseases, predominantly ones associated with the invasion of 
fibroblast cells or scar tissue into the interstitium of the lung [11]. A specific type 
of ILD is idiopathic pulmonary fibrosis or IPF. Idiopathic means that the etiology 
of the disease is not known, though there is an association with smoking [30]. 
Pulmonary fibrosis may also result from other environmental exposures, such as 
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inhalation of fibrogenic dusts or aerosolized organic antigens, drug toxicity, 
systemic diseases, or occur as an isolated, sporadic disease [12,13]. Often 
contrasted with emphysema (the loss of lung tissue and alveolar destruction), 
IPF is characterized by the findings of usual interstitial pneumonia (UIP), 
including the invasion and proliferation of patchy groups of fibroblast cells in the 
lung parenchyma, extracellular matrix deposition, abnormal alveolar remodeling, 
and enlarged air spaces lined with epithelium called honeycomb lung [12,30,31]. 
IPF is a relatively quick acting, irreversibly, and lethal disease [32] with 
symptoms including shortness of breath, a dry hacking cough, unintended weight 
loss, fatigue, and malaise. Many people are likely to die within 3-5 years after 
their diagnosis [10]. 
 
Like COPD/emphysema, IPF is a disease that displays heterogeneity within and 
across patients. Specifically within a patient’s lung, there can be the presence of 
histologically normal tissue, fibroblast foci in other places, and 
scarring/honeycomb change in others [31]. There is also heterogeneity between 
patients including age of the onset of disease, the symptoms displayed by 
patients, response to therapy, and overall presentation [31]. Like 
COPD/emphysema, there are no cures or good therapies that can reverse or 
stop the progression of IPF [33], and both abnormal lung aging [34] and aberrant 
wound healing [35] are proposed as potential mechanisms underlying the 
pathogenesis of IPF. However, the wound healing process [36] differs in that 
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rather than a loss of tissue as in emphysema, there is an overabundance of 
fibrotic scar tissue. In recent years there has been some progress in the 
understanding of the molecular mechanisms that underlie the lung response to 
injury and lead to fibrosis or emphysema like lesions in animal models of 
disease, but we still have little understanding of the molecular mechanisms and 
pathogenesis that lead to the abnormal lung phenotype in both diseases in 
humans.  
 
1.3. High throughput transcriptomics using RNA-sequencing 
Next generation sequencing has provided a huge opportunity to gain 
unprecedented insights into mammalian genomes and transcriptomes [37]. Also 
known as HTS, these techniques use methods that go beyond classic Sanger 
sequencing methodology and allow the sequencing of millions of short reads (50-
250 bp in length) that can be mapped back to a reference genome and used to 
identify subject specific genomic features. By utilizing cDNA libraries converted 
from RNA, RNA-sequencing of the whole transcriptome is possible [2,37,38]. 
Unlike array based technologies, which utilize probe hybridization to assess 
transcriptomic expression, no understanding of the transcriptomic sequences of a 
species is needed in order to perform RNA-sequencing. RNA-sequencing also 
provides the possibility of developing a more accurate understanding of the 
transcriptome as well as more precise measurements of expression and 
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alternative splicing than previous genome wide methods [38]. Recent application 
of high-throughput sequencing methods to the human transcriptome has 
provided us with an opportunity to gain an unbiased and updated view of the 
transcriptome and RNA-changes associated with disease [2].  
 
Beyond the advances in sequencing technologies, there have also been 
advances in the techniques for analyzing RNA-sequencing. Due to the large 
amount of short read sequencing data, speedier short read aligners were needed 
to align to the human genome. A major advance was to utilize a Burrow-Wheeler 
index based on the Burrow-Wheeler transform [39]. This was first used in the 
Bowtie algorithm [40,41], and also utilized by other algorithms such as BWA [42]. 
Due to the gapped nature of the transcriptome, an extension of Bowtie called 
Tophat was created that could align reads to the genome while also being able to 
align reads that overlapped splice junctions. This worked by splitting the reads 
into fragments and initially aligning the fragments, identifying potential splice 
junctions within the unaligned reads (including novel splice junctions), and then 
realigning the fragments that did not initially align to the splice junctions identified 
by Tophat [43]. At this point, one has aligned reads to the genome and could use 
a known transcript annotation such as Ensembl [44]  or UCSC [45] to analyze 
transcript expression, however, in many cases there was a need to derive the 
transcriptome in a data-driven manner. A tool called Cufflinks was created to 
address this need, and it was developed to create a parsimonious transcript 
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assembly that accounts for all aligned reads against a genome [46]. A version 
was also developed that utilized a known transcript annotation to guide the 
assembly and further improve the gene models created from the RNA-seq data 
[47].  
 
1.4. High throughput transcriptomics, alternative splicing, and 
transcriptome assembly in the context of chronic lung diseases 
To date, there have been few high-throughput gene expression studies of COPD 
and IPF. A small number of gene expression studies have characterized genes 
associated with COPD and/or emphysema and within these published genome-
wide gene expression studies on COPD lung there was limited gene expression 
overlap [48-53]. On the other hand, work using enrichment-based methods such 
as Gene Set Enrichment Analysis [54] has shown that there is more overlap in 
pathways and gene ontology between these datasets than initially perceived [55]. 
Gene expression studies in IPF have been limited to just a few studies as well 
[32,56-58]. More importantly, despite the evidence that convergent mechanisms 
exist in IPF and COPD (such as age [34] and aberrant wound healing [29,35] and 
that direct comparisons of the diseases may be mechanistically informative [59], 
they are still studied in isolation. Given the limited scope of expression studies in 
COPD and ILD, and that COPD and IPF have traditionally never been profiled in 
parallel, larger studies with more aggressive transcriptome profiling is necessary 
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to better characterize the shared molecular basis of COPD and IPF as well as 
develop improved and more tailored treatments. 
 
Furthermore, there are no genome-wide studies of IPF or COPD/emphysema 
that examine isoforms and alternative splicing as it relates to disease, nor are 
there any studies that have performed RNA-seq on lung tissue samples from 
patients with COPD/emphysema or IPF. Although, there have been candidate 
alternatively spliced genes identified in COPD, an example being that 
phosphodiesterase type 4 inhibitor isoform A4 was found significantly 
upregulated in lung macrophages from smokers with COPD when compared with 
control smokers without COPD [60]. There is also some evidence that alternative 
splicing of the X-box-binding protein 1 can associates with lung fibrosis in aged 
mice, but beyond this, there has been little work done to examine how alternative 
splicing may play a role in the pathogenesis of IPF [61]. 
 
By performing RNA-seq on lung tissue samples from the Lung Genomics 
Research Consortium, we’re given the opportunity to quantitatively examine the 
structure of millions of sequences of mRNA fragments from patients with 
COPD/emphysema, ILD/IPF, or control lung. The single-nucleotide resolution of 
this approach provides the potential to gain unprecedented insights into the 
structure of the chronic lung disease transcriptome that would have not been 
possible in previous whole genome microarray studies of these diseases. Lastly, 
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the identification of splicing events and novel transcripts associated with these 
diseases will help us to better understand the pathogenesis of these diseases in 
ways that would not have been possible in the previous whole genome 
expression studies mentioned above. These novel transcripts and differential 
splicing events could perform as biomarkers of COPD/ILD and even help 
elucidate the heterogeneous differences between patients in order to find better 
targets for therapy. Up to now, this thesis work is one of the largest works 
sequencing lung tissue RNA, and, outside of the Illumina Human BodyMap 2.0 
dataset [62], one of the few projects to perform high throughput RNA-sequencing 
on human lung tissue samples in order to gain a better understanding of the lung 
transcriptome.  
 
1.5. Dissertation aims 
Utilizing next generation RNA-sequencing technology provides the ability to 
explore the transcriptomic landscape of the lung, identifying what is and is not 
expressed, as well as looking at genome wide changes in alternative splicing. 
We can further utilize the millions of RNA-sequencing reads per sample to 
assemble and annotate a transcriptome based solely on what reads are 
expressed in lung tissue samples, and with this we have the ability to identify 
entirely novel regions of expression within the transcriptome. Even more, by 
identifying novel loci and splicing  associated with chronic lung disease, we could 
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find new insights into the pathogenesis of these diseases as well as potentially 
novel targets for therapy.  
 
Aim 1. Gain a global perspective on the transcriptomic landscape of human 
lung tissue samples 
By examining the behavior of known genes across an initial set of lung tissue 
samples from the LGRC, we will define the behavior of the known lung 
transcriptome using RNA-seq. We will use a mixture model to separate gene 
expression distributions and identify reliably expressed genes in each RNA-seq 
sample. Doing this will allow us to compare expression variability between 
samples as well as between conditions (namely between control, IPF, and 
COPD/emphysema lung tissue samples). We will be able to identify which genes 
are reliably expressed in the lung, which vary, and identify the pathways 
associated with those genes. Furthermore, we will look at the transcriptomic 
potential of the lung by comparing the transcriptomic landscape of the sequenced 
lung tissue sample in the Illumina Human Body Map data to other organ samples 
(Chapter 2). 
 
Aim 2. Explore chronic lung disease associated alternative splicing in RNA-
sequencing to gain a deeper understanding of transcript level changes in 
COPD and IPF. 
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In order to utilize the power of RNA-sequencing, we aim to work on identifying 
alternative splicing changes associated with COPD or IPF lung tissue samples. 
Assigning short reads to specific isoforms of a gene is difficult in that many reads 
can be assigned ambiguously to multiple isoforms. To get around this we will 
explore the possible models that already exist for identifying alternative splicing, 
and expand on them by harnessing the reads that overlap splice junctions. We 
will develop a model for identifying the interaction between splice junctions and 
disease association in order to identify genes that are likely to have changes in 
splice junction that associate with disease. By using know tissue specific 
alternative splicing in the human body map samples we will identify the better 
methodology. We will then identify alternative splicing in both IPF and COPD 
samples and look for both shared and divergent changes in splicing between the 
disease groups. This will give us higher resolution view of transcriptional changes 
between control lung tissue samples and disease. (Chapter 3) 
 
Aim 3. Assemble a chronic lung disease de novo transcriptome and 
identify and classify novel loci and transcripts whose expression 
associates with chronic lung disease 
A crucial task will be to first develop and improve a pipeline that will take us from 
RNA-sequenced data to a final reference based genome-guided transcriptome 
assembly using Cufflinks. In order to improve on this process, we’ll examine the 
parameters and output of each step of the pipeline and work towards improving 
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the final assembly by removing features with low evidence or that are likely to be 
noise or due to limitations in the RNA-sequencing experiment (Chapter 4). After 
developing a final transcriptome assembly, we will identify novel loci and 
transcripts by comparing them to current annotated known transcriptome 
assemblies. Loci and transcripts that do not overlap with known transcripts will be 
flagged as novel. We then aim to computational examine the novel loci and 
transcripts to identify their likely coding or non-coding status. Finally, with this 
subset, we’ll identify those novel loci and transcripts that are differentially 
associated with either COPD/emphysema or IPF, in order to identify new targets 
for future functional studies in these chronic lung disease. Overall, this final step 
will be an example of how to fully utilize next generation RNA-sequencing to 
discover novel regions of expression associated with chronic lung disease. 
(Chapter 5) 
 
2. GAINING A GLOBAL PERSPECTIVE ON THE 
TRANSCRIPTOMIC LANDSCAPE OF HUMAN LUNG TISSUE 
2.1. Introduction 
2.1.1. The Lung Genomics Research Consortium 
Lung diseases, such as pulmonary fibrosis, COPD, and emphysema, have 
traditionally been defined by objective clinical characteristics (history, physiology, 
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radiography, and pathology). Although these classification systems have led to 
some advances in understanding the pathogenesis and clinical expression of 
these disease processes, these approaches fall short of addressing the unique 
etiology and evolution of a disease within an individual. While these clinically-
based diagnostic categories of lung disease are helpful, molecular tools are now 
available to identify conditions in their early asymptomatic stages and to account 
for the great heterogeneity in disease expression with the goals of improved 
prediction of outcome and development of personalized approaches to treatment. 
This is where the Lung Genomics Research Consortium (LGRC) comes in. The 
overall goal of the LGRC was to establish a genetic, molecular, and quantitative 
phenotyping warehouse for the lung research community that would enable 
investigators to develop and test hypotheses to understand the etiology, 
pathogenesis, and clinical manifestation of non-malignant chronic lung diseases.  
 
The samples utilized by the LGRC come from the NHLBI Lung Tissue Research 
Consortium (LTRC), which was created provide human lung tissues and DNA to 
the research community from subjects with well-defined clinical phenotypes. This 
program enrolls donor subjects prior to lung surgery, collects blood and clinical 
data from the prospective donors, and then processes their excess surgical 
tissues for research use. The samples from the LTRC are molecular profiled by 
the groups participating in the LGRC. The Spira pulmonomics lab is the group in 
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the LGRC that specifically focused on doing large- and small-RNA-sequencing 
on the ILD/IPF, COPD/emphusema, and control lung tissue samples. 
 
2.1.2. Examining the transcriptomic landscape of lung tissue samples 
There are two reasons to look at whether a gene is expressed or not in an RNA-
sequencing sample: 1) To gain a global understanding of what is and is not 
expressed across samples and 2) to identify the genes that are observed to be 
generally lowly expressed and thus should be filtered out before doing more 
downstream analysis such as differential expression. Due to the continuous 
analog nature data from Affymetrix microarray experiments, such as those 
performed by Spira et al. [63], a gene or probeset could be defined as being 
expressed if it was found to be detected above the background signal of each 
array. A Wilcoxon test was used by the original Affymetrix software to assign a 
detection p value that could be used to decide whether a transcript was reliably 
detected or not. Spira et al. were then able to define the normal large airway 
transcriptome by choosing genes that had a median detection p value < 0.05 
across their samples [63].  
 
On the other hand, since RNA-seq gives digital counts per loci and these counts 
are dependent on the library size, there is not as obvious of a way to decide 
whether or not a locus is reliably detected and how one should go about filtering 
out genes with low level expression for downstream analysis. Some groups use 
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hard cutoffs such as excluding a transcript if the total number of reads aligning to 
it are less than a certain cutoff (typically 1-20 reads). For example Bullard et al. 
define a gene as present if it has at least 1 read in two samples, and then filter 
genes further down to genes that have at least 20 reads across samples [64]. 
Other ways of filtering the presence or absence of gene expression include: 
filtering by RPKM (Reads Per Kilobase of exon model per Million mapped reads 
[2]), such as the 0.3-0.8 RPKM threshold defined by [65] or filtering by the 
minimum number of reads that overlap at base level [66].  
 
Considering the number of arbitrary decisions involved in many of the above 
steps, we wanted to find a more empirical way to separate genes that are 
expressed from those that are not In the next section, we show that genes 
generally separate into a mixture of log-normal distributions that can be 
separated utilizing a mixture model. We then were able to define whether genes 
were reliably expressed or not in each sample. From this we could look at the 
transcriptomic landscape of lung tissue samples in the LGRC as well as compare 
lung tissue samples from the Illumina Human Body Map [62] to other organs to 
see how the landscape behaves between tissue types.  
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2.2. Results 
2.2.1. Study design: Sample collection from the Lung Tissue Research 
Consortium and Patient Demographics 
All lung samples were acquired from the Lung Tissue Research Consortium 
(LTRC) [67] and utilized by the Lung Genomics Research Consortium (LGRC) 
[68], both supported by the National Heart, Lung, and Blood Institute (NHLBI). 
Patient clinical information, pulmonary functions, demographics, imaging results 
and pathology and clinical diagnoses were available. An initial set of 87 samples 
were sequenced for the analysis of the global lung transcriptome (Table 1). 
These 87 samples were sequenced and initial analysis focused on a subset of 75 
patients with the clearest phenotypes based on pathological analysis, 
specifically: control, COPD with emphysema (% emphysema > 30), COPD 
without emphysema (% emphysema < 10), and IPF phenotypes. This subset of 
patient samples was also matched for age, smoking history, and gender (Table 
2). Overall, the samples from the LTRC generally had high RIN values. All 
studies were approved by the Institiutional review Boards at participating 
institutions and per LTRC protocol all patients signed informed consent. 
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Table 2: Demographics of the 75 lung tissue samples from the LGRC 
 
 
IPF 
Emphysema 
(>30 %emp) 
Airway COPD 
(< 10 %emp) 
Control 
# of samples 19 19 17 20 
Age 64.0 ± 9.2 56.3 ± 8.7 68.4 ± 10.4 62.3 ± 10.0 
Sex 15 M , 4 F 10 M, 9 F 12 M, 5 F 11 M, 9 F 
Race 
19 CAU 18 CAU,  
1 AFA 
17 CAU 18 CAU, 2 
AFA 
Smoking 
status 
17 Former,  
2 Never 
18 Former,  
1 Never 
15 Former (2) 1 Current,  
15 Former,  
2 Never (2) 
Pack years 31 ± 23 (2) 48 ± 27 (1) 51 ± 23 (2) 27 ± 23 (4) 
% DLCO 40 ± 15 (1) 32 ± 10 (7) 74 ± 12 (2) 81 ± 18 (2) 
FEV1% 
predicted 
78.0 ± 5.3 
(14) 
24.5 ± 8.5 (7) 70.1 ± 21.7 96.4 ± 8.6 (6) 
% Emphysema 1.7 ± 2.6 (7) 47.5 ± 9.1 2.3 ± 2.0 0.8 ± 1.3 (9) 
 (Numbers in parenthesis are missing values) 
Table 1: Demographics of the 87 lung tissue samples from the LGRC 
 ILD COPD Control 
# of samples 23 43 21 
Age 62.4 ± 9.8 60.8 ± 10.7 62.0 ± 9.8 
Sex 18 M, 5 F 24 M, 19 F 12 M, 9 F 
Race 22 CAU, 1 AFA 41 CAU, 2 AFA 19 CAU, 2 AFA 
Smoking status 
19 Former, 3 
Never (1) 
40 Former, 1 
Never (2) 
1 Current, 15 
Former, 3 Never (2) 
Pack years 29 ± 23 (4) 50 ± 26 (3) 27 ± 23 (5) 
% DLCO 37 ± 16 (2) 50 ± 24 (10) 82 ± 18 (2) 
FEV1% predicted 71.8 ± 15.8 (17) 50.4 ± 27.9 (11) 96.4 ± 8.6 (7) 
% emphysema 2.1 ± 2.9 (10) 26.0 ± 22.1 (2) 0.76 ± 1.2 (9) 
 (Numbers in parenthesis are missing values) 
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2.2.2. RNA-sequencing data from the Lung Genomics Research Consortium 
aligns with high quality to the human genome 
A range of 18-46 million (average: 32 million) 75 nt paired-end reads were 
obtained from each sample and a high percentage(average: 28 million) of these 
reads aligned to the genome using conservative alignment parameters.  
Specifically, 85.9±6.9% of reads aligned to the genome. Of the aligned reads, 
90.3±4.8% were aligned as paired ends (of which 88.7±3.8% were properly 
paired), 9.04±4.8% were aligned as singletons and 81.4±3.1% aligned uniquely 
to the hg19 human genome. The alignment statistics across the samples indicate 
that the RNA-seq data obtained from the LTRC tissue samples is high quality 
(Figure 1, Figure 2). 
 
 
Figure 1: Alignment statistics for 87 LGRC samples. A majority of the reads in the 
first 87 samples align to the human genome when utilizing Tophat v1.2. Most of the 
reads also align uniquely.
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Once the reads were aligned, we used Cufflinks to get normalized gene level 
expression values using FPKM or Fragments Per Kilobase of exon model per 
Million mapped reads (the major fragments and reads is that paired end reads 
are counted as a single fragment whereas with RPKM, they are counted as two 
reads). FPKM is actually a misnomer because the FPKM value given when using 
the quartile normalized data parameter in Cufflinks is not normalized to the library 
size and instead is the number of fragments per kilobase of exon model per the 
upper quartile of the read counts of over all of the genes.  
 
 
Figure 2: Mismatch statistics for 87 LGRC samples. In most samples, ~90% of 
the reads align with 1 or less mismatches to the human genome. Reads with > 3 
mismatches are generally around 1% or less of the reads that align successfully.
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2.2.3. Using a mixture model to identify reliably expressed genes in an 
RNA-seq sample 
When utilizing RPM, RPKM, or Cufflinks FPKM, most RNA-sequencing libraries 
tend to have a distribution of expression per gene that looks like a mixture of two 
distributions (Figure 3a). Generally there is a large set of genes that have zero 
reads, influencing the lower distribution, but even if we remove those reads, we 
still see a mix of expression values that correspond to either lower expressed 
genes or generally higher expressed genes (Figure 3b). The stochastic nature of 
gene expression is one of the potential reasons behind this bimodal nature of 
gene expression [69-71]. This bimodal distribution of lower expressed genes, or 
noise, and more reliably expressed genes could be explained potentially by leaky 
transcription [72] or the combination of transcription rate and mRNA degradation 
in the cells in the cells [73]. As mentioned in the introduction of this chapter, 
many previous studies tend to select somewhat arbitrary ways to decide how to 
classify the behavior of loci within a transcriptomic dataset. Instead of doing this, 
we decided to utilize a mixture modeling method to try and separate lowly 
expressed transcripts or “noise” from those reliably expressed transcripts or 
“signal”. 
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In order to separate the two distributions, we used a mixture model function 
modified from the one developed by Piccolo and Johnson et al called UPC or the 
Universal Probability of expression Codes [74]. This mixture model fits two log 
normal distributions from the data and returns a probability that the gene is found 
in one or the other distribution. We fit the two log-normal distributions to the gene 
expression data within a each RNA-sequencing sample and were able identify 
which of the two distributions a gene was more likely to come from (Figure 4). 
 
 
Figure 3: Histogram of gene expression behavior in single LGRC RNA-seq 
sample. 3a) This plot shows a histogram of the ensembl59 genes as they are 
expressed in a single sample including the genes with zero read counts. 3b) When 
the zero counts are removed, we see that there is a mixture of two distributions within 
the genes that have some expression/read alignment. 
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This mixture model allowed us to separate the genes into those that are reliably 
expressed and those that are not reliably expressed in a data derived way that 
did not require us to choose an arbitrary cutoff.  
 
2.2.4. Characterizing the Lung Transcriptome in COPD and IPF 
To identify genes reliably expressed across all lung tissues, we utilized the UPC-
based mixture modeling method to distinguish between genes with clear 
expression signal from genes with zero or so few aligned. This analysis was 
 
Figure 4: Fitting the lognormal mixture model to an RNA-seq samples. In this 
plot we highlight the distribution of the original data using a histogram. The fitted 
mixture model is displayed as the red density plot line on top of the histogram, and 
the green line shows the point in the model where the probability of a gene coming 
from the lower distribution switches to favor the right most distribution. 
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performed on each of the 87 samples and each sample showed a similar number 
of genes in the three categories: signal, noise, and zero (Figure 5a, box plots). 
Next, each gene was examined across the 87 samples to see if it was an 
‘always” signal , a ‘never’ signal, or a ‘variably expressed’ signal across all 87 
samples in order to characterize the landscape of expression across the lung 
transcriptome (Figure 5b, waterfall/landscape figure). Of the 24297 
experimentally known Ensembl release 59 genes, 7767 are constitutively 
expressed (‘always’ signal across the 87 samples), 8756 are never expressed 
(‘never’ signal across the 87 samples), and 7774 are variably expressed. 
 
 
Figure 5: Transcriptomic behavior and landscape. 5a) The number of signal 
genes, noise genes, and zero genes were counted for each sample. A box plot was 
then made of the signal, noise, and zero counts across the 87 samples showing 
within a sample, approximately half of the ensemble 59 genes were reliably 
expressed. 5b) For each gene, how often in each sample it was called “signal” was 
counted. This plot shows that about 1/3rd of the genes are always expressed 
confidently in all the lung tissue samples and 1/3rd are never reliably expressed in 
lung tissue samples.
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In order to better understand the transcriptional potential repertoire of the lung we 
looked at which genes were reliably expressed in each disease subtype as well 
as the overlap across all samples. We identified genes that were always 
expressed across samples within each phenotype – control (n=20), COPD with 
emphysema (n=19), IPF (n=19), airway COPD (n=17). A majority of the genes, 
(77.9%) that were always expressed in each of those subsets overlapped with 
one another (Figure 6). Gene ontology analysis performed on the lists of genes 
identified as always expressed across all samples and within each phenotype 
showed that the majority (76%) of the KEGG pathways [75] that were 
significantly enriched (q < 0.05) were shared across all 5 groups (Figure 7). The 
data suggest that there are strong similarities in what is reliably expressed in the 
lung transcriptome regardless of disease subtypes.  
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Figure 6: Venn diagram of overlap of genes always reliably expressed within 
phenotypes. This diagram looks at the four phenotypes that add up to the 75 lung 
tissue samples. The genes shown here are the ones that are always reliably 
expressed across the samples within each phenotype. The overlap of the 4 sets of 
genes shows that a huge majority of genes that are always reliably expressed in one 
set of phenotypes is also generally always expressed in the other phenotypes.
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Figure 7: Circos plot of the significant KEGG pathways of genes always reliably 
expressed. This circus plot displays the large number of pathways that were 
significantly enriched among genes that are always reliably expressed in each of the 
87 lung tissue samples (blue), in each of the 20 control samples (grey), 19 IPF 
samples (yellow), 19 emphysema samples (red), and 17 airway copd/minimal 
emphysema samples (purple). The plot shows all of the KEGG pathways significant 
using FatiGO gene ontology analysis in the genes that were always reliably 
expressed for at least one of the five groups mentioned compared to remaining 
genes in the genome. Starting at the 12 o’clock position and going clockwise, the 
thick black line encircles those pathways that were significant in all five groups, 
followed by the pathways found in just 4, 3, 2, and only 1 group respectively. The 
ideogram of gray bars represents each pathway and the variable lengths of those 
bars represent the differing number of genes in each pathway. 
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In order to get an idea of how being always expressed or variably expressed 
across the samples can relate to differential gene expression, we compared the 
number of genes that are DE expressed in IPF v CTRL and EMP v CTRL at q < 
0.1 to see which category of expression they fall into in the transcriptomic 
landscape. The DE gene analysis was performed by my colleague, Rebecca 
Kusko, and I utilized the output of that analysis in this step. As expected, no DE 
genes are found in the list of genes that are never expressed across the 87 
samples. However, in the IPF samples, 51% of DE genes are always reliably 
expressed across the 87 samples whereas 49% of DE genes are found to be in 
the variably expressed categories. For emphysema DE genes, this observation is 
a little more skewed towards the always reliably expressed genes with 61 
percent of DE genes being found in the genes that are always signal across the 
87 samples (and 39% of DE genes being variably expressed across the lung 
tissue samples). This shows us that in some cases genes that are reliably 
expressed (but still vary in absolute expression differences across samples) are 
slightly more likely to contain more of the genes that are DE expressed than in 
the variably expressed category. 
 
Next, I compared lung tissue samples to other organs via RNA-sequencing, we 
utilized the sequenced tissue data from the Illumina Body Map dataset. The Body 
Map data contains 16 tissue types that have been sequenced using Illumina 
protocols (n=1 for each): white blood cells, skeletal muscle, adipose, liver, heart, 
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thyroid, adrenal, breast, ovary, colon, brain, kidney, lymph node, prostate, testes, 
and lung tissue. I specifically used the 50 nt paired end RNA-sequencing data 
from Illumina. The mixture model was applied to the Tophat/Cufflinks aligned 
data for each tissue, and returned the signal/noise behavior for each gene in 
each sample. By comparing the number of genes that were classified as signal 
between tissues (Table 3), I was able to identify that, out of the 16 tissue types, 
lung tissue had the largest number of genes reliably expressed (13640 genes) 
followed by testes (13,363). White blood cells and skeletal muscle actually had 
the fewest genes reliably expressed (10985 and 11261 genes respectively). This 
shows that lung tissue, within the Illumina Body Map samples, may have the 
largest transcriptional potential, likely because of the sizeable mixture of cell 
types that make up lung tissue.  
 
 
Table 3: Number of genes reliably expressed per tissue in Illumina Human 
Body Map data. 
 
Tissue # Signal genes Tissue # Signal genes 
lung 13640 breast 12247 
testes 13363 adrenal 12156 
prostate 13202 thyroid 12046 
lymph node 13131 heart 11795 
kidney 12749 liver 11598 
brain 12611 adipose 11320 
colon 12607 skeletal muscle 11261 
ovary 12410 white blood cells 10985 
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2.3 Discussion 
Currently, this is one of the largest studies of RNA-sequencing studies ever 
performed on human lung tissue samples from control, ILD (with a specific focus 
on IPF), and COPD (with a focus on emphysema) subjects. Overall, the RNA 
sequencing yielded high quality data with most of the reads aligning to the 
genome with very few mismatches overall. 
 
We used 87 samples to conservatively characterize and define what genes are 
expressed across the lung tissue samples in order to define the lung tissue 
transcriptome. We also examined 4 clinically defined subsets (n = 75, types: 
control, IPF, emphysema, and airway COPD) of these 87 samples to highlight 
the large overlap of genes that are reliably expressed across these four 
phenotypes. Within each sample we were able to classify genes as having no 
detected expression by RNA-seq, reliably expressed, and detected but likely to 
be transcriptional noise rather than active expression. Generally, within each 
sample, approximately half of the known transcriptome is reliably expressed as 
shown by Figure 5a. We then classified the transcriptome by counting the 
number of samples a gene was reliably expressed in. Interestingly, 32% of genes 
were reliably expressed in all 87 samples, 36% of genes were never reliably 
expressed in all 87 samples, and 32% were variably expressed in anywhere from 
1 to 86 samples as seen in Figure 5b. Therefore, in the lung transcriptome we 
see that, despite the disease phenotypes of subsets of the 87 samples, we can 
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conservatively postulate that at least around a 1/3rd of the known genes are 
constitutively active in the lung tissue samples profiled.  
 
We also wanted to characterize how well genes were reliably expressed within 
specific phenotypes and saw that there was a very large overlap of genes always 
expressed across samples within the 4 subcategories of control, IPF, 
emphysema, and airway COPD as profiled in Figure 6. To look at what pathways 
are reliably expressed in all samples as well as within specific phenotypes, we 
used a circos plot to display the significant (q < 0.05) KEGG pathway [75]. What 
we see here is that of the pathways that are significantly enriched, there is not a 
significant variability within disease phenotypes. One reason we postulated that 
this was the case is due to the large number of cell types within lung tissue that 
could be expressing different types of pathways. By looking at how the lung 
tissue sample behaved and comparing it with other organ tissue samples in the 
Illumina Human Body Map data, we confirmed that more genes were reliably 
expressed in lung tissue than in any of the other tissue samples and confirmed 
the larger transcriptional potential occurring in the lung tissue. Overall, we were 
able to give a descriptive overview of the lung transcriptome as a whole in these 
87 lung tissues as well as within subcategories. By identifying how genes are 
categorized in each sample, we can better filter genes in downstream analysis in 
order to remove the genes that would not be interesting due to low or no 
expression across the samples. 
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2.4 Methods 
2.4.1. Sample Considerations 
An initial set of 89 samples were evaluated for potential field of cancerization 
effects because two (control and most of the emphysema samples) out of the 
four phenotype groups originated from areas adjacent to cancer. The samples 
were mined for abnormal gene fusions and cytogenetic abnormalities in the lung 
and blood allele balance. Two control samples contained between 12% and 25% 
abnormal cells by allele balance via the Illumina Infinium assay. This could be 
due to small metastases or to premalignant changes in the uninvolved lung due 
to the cancer field effect. Therefore, 2 control samples were removed based on 
abnormal copy number variation.   
 
Of the remaining 87, 75 samples were selected by pathologists  as displaying the 
cleanest phenotypes for further downstream analysis. The COPD categories 
were defined based on the percent of emphysema pathology measurement. 
COPD samples that had mostly had <10% emphysema and >30% Emphysema 
were used to make a cleaner airway COPD and emphysema phenotype. The ILD 
samples were subset down to those with an IPF phenotype as per ATS criteria 
[30] 
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2.4.2. Library Preparation and Sequencing  
We have successfully completed library preparation and sequencing of the 
mRNA for each of the 89 LGRC samples (n=19 COPD subjects with predominant 
Emphysema phenotype, n=17 COPD subjects without predominant emphysema 
phenotype (suspected airways disease), n=19 IPF subjects, n=13 COPD 
subjects with intermediate emphysema phenotype, and n=20 controls 
(histologically normal tissue samples usually adjacent to cancer nodules). The 
library preparation was done using Illumina’s mRNA Sequencing Sample 
Preparation kit starting with 1 μg of total RNA. The mRNA was isolated using 
poly(A) selection, fragmented, and randomly primed for reverse transcription 
followed by second-strand synthesis to create double-stranded cDNA fragments. 
Ends were repaired, ligated to Illumina Paired-End sequencing adapters, and 
fragments of around 300 bp were obtained through gel-based size selection (200 
bp library size + 2x50bp adapters). These fragments were PCR amplified, 
purified, and then subjected to cluster generation using Illumina Paired-End 
Cluster Generation Kit v4. Each sample was sequenced singleplex on 1 lane of 
an Illumina Genome Analyzer IIX to generate 30-40 million 75 bp paired end 
reads having an average inner distance between mate pairs of 50 bp. 
 
2.4.3. RNA-Seq Data Processing 
Initial data processing was done using Illumina GA pipeline version 1.3. The 
quality of each sample sequenced was assessed by looking at several Illumina 
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metrics such as the percent (%) of clusters passing the filter, the density of the 
cluster passing the filter, and the number of sequencing cycles with a median 
phred quality score less than 30. In addition, we examined the distribution of the 
quality scores as a function of position, the nucleotide composition as a function 
of position, and histograms of the inner distance between paired end reads 
mapped to the genome using our own custom perl scripts as well as the FastQC 
java program by Simon Andrews at Babraham Bioinformatics [76]. 
 
Data analysis from this point on was completed using R version 2.11.0. After 
samples were evaluated for quality, we aligned the samples to the human 
genome using Tophat version 1.2 [43]. Tophat is a gapped aligner specifically 
optimized for RNA-seq data which  identifies the reads that align to the genome 
as well as reads that span known and novel exon-exon splice junctions. The 
reads were aligned as a pair and were allowed up to 2 mismatches per 25 bp. 
The tophat default  number of 40 multi-reads was also allowed. Tophat was run 
by specifying Illumina GA pipeline version 1.3 or greater, unstranded library, a 
mate inner distance of 50, and a mate standard deviation of 100bp. After 
alignment, samples are again assessed for quality by examining the number of 
reads that aligned uniquely and the number of reads that aligned with varying 
number of mismatches. The first and second principle components were also 
assessed as part of post-alignment quality control.  
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The results of the gapped alignment were used to quantify the number of reads 
mapping to each gene. We generated gene level expression estimates for each 
of the 87 samples using Cufflinks Version1.1.0 [46,47]. The gene annotation for 
genes containing multiple transcripts was created by including common and 
unique regions of each transcript. Cufflinks was run to only quantify known 
transcripts through the use of a modified Ensembl 59 GTF. Furthermore Cufflinks 
was run such that it performed upper quartile normalization, mutliread correction, 
and nucleotide bias correction.   
 
2.4.4. Utilizing a Mixture Model of Gene-level FPKM Data to Flag Genes as 
“Signal”/”reliably expressed” or “Noise” 
Genes were defined as “signal/ reliably expressed” or “noise/zero” using a 
mixture model. The mixture model utilized the quantified gene-level FPKM values 
from the Cufflinks output using Ensembl 59 (only known genes). In most 
individual RNA-seq samples, once all genes where zero reads were aligned are 
removed, the remaining distribution of genes appears to be a mixture of two 
distributions of expression values. One of these occurs on a lower read count 
level, and the other appears at a more highly expressed read count level. The 
mixture model was developed to conservatively fit two natural log-normal 
distributions to the natural log of the FPKM data from Cufflinks in order to 
separate those two distributions. We fit each RNA-seq sample to this model 
using a converging expectation maximization algorithm written in R [74]. Next, 
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genes were filtered down to only the Ensembl gene ids flagged as “Ensembl” and 
“Known” in Biomart [77,78]. Within each sample, genes were then assigned as 
“zero/noise” if no reads aligned to those genes or if they were assigned into the 
higher expression distribution by the model with a probability of less than 50%. 
Genes were labeled as “signal/reliably expressed” if they had a 50% or greater 
probability of being in the more highly expressed natural log-normal distribution.  
 
These “signal/reliably expressed” and “zero/noise” definitions were used to define 
a set of genes which are always expressed, variably expressed, or always not 
expressed across all 87 samples sequenced in order to define a conservative 
lung transcriptome. The models conservatively underestimate what is always 
expressed and overestimates what is never expressed because the total number 
of reads obtained per sample limits the noise distribution in the mixture model. 
 
2.4.5. Gene ontology 
The Babelomics’s tool FatiGO (version 4.2) was used to identify significant 
KEGG pathways   associated with the list of genes that were always expressed 
or not across the lung tissue samples in order to define the known transciptome 
across lung tissue samples. The FatiGO tool works by comparing a gene list to a 
background list of all the genes remaining in the genome in order to identify GO 
terms that are significant for the interesting gene list and simultaneously not as 
significant in the background genome that remains [79-81]. 
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2.4.6. Circos plots 
In order to visualize the large number of significant KEGG results [75] across the 
4 phenotypes and the group of 87 samples, we utilized circos plots [82]. Circos 
allowed us to make a circular representation of all the pathways from the FatiGO 
KEGG analysis [80] that were significantly enriched in at least 1 or more of the 
five groups. We specifically used the “heatmap” function of the circus software to 
plot the significant KEGG groups around the ideogram of pathways.  
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3. EXPLORE CHRONIC LUNG DISEASE ASSOCIATED 
ALTERNATIVE SPLICING IN RNA-SEQUENCING TO GAIN A 
DEEPER UNDERSTANDING OF TRANSCRIPT LEVEL CHANGES 
IN COPD AND IPF 
3.1. Introduction 
3.1.1. An overview of spliced isoforms and alternative splicing 
Alternative splicing is one of the main post-transcriptional mechanisms that can 
account for the large diversity in protein products that make up complex 
organisms. One of the major differences between the genomes of prokaryotic 
and eukaryotic organisms is that, unlike in prokaryotes, the mRNA of eukaryotes 
is discontinuous in sequence compared to the pre-spliced pre-mRNA 
transcription product of a gene. The gene sequences that remain in the mature 
mRNA are known as exons and the removed sequences are known as introns 
[83].  
 
Unlike the original dogma of one gene, one protein, which led to incorrect 
estimations that 30,000-100,000 genes would be found in the human genome, it 
is the ability for transcribed mRNAs to be post-transcriptionally spliced into 
different RNA isoforms that can account for the counterintuitive finding that 
complex organisms can have low numbers of protein coding genes [84]. 
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Alternative splicing can be categorized into different types of splicing, namely 
cassette exon skipping/including, mutually exclusive exons, intron retention, 
alternative 3’ or 5’ donor/accepter sites, alternative promoters, and alternative 
poly-A sites (Figure 8). The most common of these is exon skipping/inclusion 
[83,85,86].  
 
 
With the continued work of groups such as the ENCODE/GENCODE projects 
[87,88], our understanding of how alternative splicing behaves in human data will 
continue to increase. For example, genes are observed to express, on average, 
10-12 isoforms per gene, far more isoforms than the 2.6-3.2 isoforms originally 
estimated from EST data as published in [89]. Usually within a specific case or 
 
Figure 8: A visual guide to the major types of alternative splicing. The most 
common splicing type is the bolded exon skipping or inclusion event.
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condition, however, one isoform is dominantly expressed compared to the others 
[90,91].  
 
3.1.2. Alternative splicing and disease 
By understanding that alternative splicing provides for a greater range of protein 
complexity, and that within cell types one isoform is generally dominantly 
expressed compared to the others, it is reasonable to extrapolate that aberrantly 
modifying the proportions of isoforms could play a role in disease. Although, as 
with gene expression, whether splicing changes are causative or a response to 
disease is not immediately apparent [92]. There are some ways that aberrant 
splicing can occur including: silent mutations that affect accepter/donor sites, 
mutations that affect the proteins that make up the spliceosome , mutations that 
affect pre-spliced mRNA secondary structure, responses to changes in 
phosphorylation and cell signaling that affect the splicing protein complexes, 
epigenetic changes including DNA methylation and histone modification that 
affect pre-mRNA, etc. [92-95]. Some diseases that are associated or caused by 
aberrant splicing include spinal muscular atrophy (mutation in regulatory region 
affecting splicing), tauopathies—the accumulation of abnormal tau protein 
filaments in the brain (caused by change in ratio of alternative splicing isoforms), 
and cancer (such as increase of P73alpha isoform versus P73beta in malignant 
prostate cancer versus non-malignant and similarly found in non-small-cell lung 
cancer cell lines) [92,96]. Since splicing plays a role in many different diseases, 
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new therapeutic approaches using small molecules and modified antisense 
oligos which target specific parts of pre-mRNA sequences and can prevent 
aberrant splicing are being developed and are in clinical trials [97,98]. It isn’t too 
much of a leap to imagine that if splicing could be shown to play a role in the 
development of chronic lung disease that similar therapeutic approaches could 
be affective.  
 
Despite this potential for exploring alternative splicing in disease, there are not 
many studies that look at it in either COPD/emphysema or ILD/IPF. Furthermore, 
there are no genome-wide studies using either exon arrays or RNA-seq that 
examine isoforms and alternative splicing as it relates to chronic non-malignant 
lung disease. Very few studies have looked at alternative splicing and chronic 
lung disease, even on a candidate level. There is some evidence that the 
alternative splicing of Titin could play a role in diaphragm dysfunction in COPD 
[99], and there is the example mentioned early of the phosphodiesterase type 4 
inhibitor isoform A4 association [100], but overall this remains an area that 
deserves greater exploration.  
 
3.1.3. A brief overview of alternative splicing methods 
Identifying differential alternative splicing is not a simple problem when utilizing 
short read RNA-sequencing. Classic approaches used original with exon arrays 
such as Spliced Index [101], ANOVA based methods [102], FIRMA [103], etc. 
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tend to be exon-centric and are adequate at identifying differential exon 
expression. However, since there is a lot of exonic overlap across known 
isoforms, I decided to utilize a different approach where we exploited the reads 
which specifically overlap splice junctions to represent alternative splicing. By 
looking at how those junctions are expressed, especially since splice junctions 
can more easily distinguish between isoforms and have less overlap than exons, 
it becomes an easier problem to explore. Generally, our method is an extension 
of the Spliced Index/ANOVA approach, but used to look at splice junctions usage 
instead of differential exon usage. Overall, by utilizing the reads that overlap in 
splice junctions in the 75 samples used in Chapter 2, I was able to identify and 
validate alternative differential splicing associated with the p53 pathway and 
wound healing in both IPF and COPD/emphysema.  
 
3.2. Results 
3.2.1. Utilizing IPF, emphysema, and control LGRC samples and aligning to 
known splice junctions using Tophat 
In this section, we again used the subset of 75 samples selected based on 
having matched demographics and distinctive phenotypes: control, COPD with 
emphysema (% emphysema > 30), COPD without emphysema (% emphysema < 
10), and IPF phenotypes (Table 2). Generally, downstream analysis (either 
differential expression or alternative splicing) of the airway COPD samples did 
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not yield significant results, so the results focus on the 58 samples that make up 
the control, IPF, and COPD with emphysema groups.  
 
3.2.1. Finding a method for identifying disease-associated alternative 
splicing 
Originally, I wanted to use the isoform-based differential splicing algorithm from 
Cufflinks called Cuffdiff. The issue I ran into, and that others groups have run into 
(see supplemental data from this paper [104]), is general inflation of the number 
of significant results from Cuffdiff that lead to lots of false positives that do not 
reflect the underlying data, even when comparing the results of changes in 
isoform expression between Cuffdiff and Cufflinks itself (Figure 9). Because of 
this discrepancy between the results returned from Cuffdiff and the results 
returned by Cufflinks, a known example of tissue specific splicing (MEF2D) was 
identified in the literature [2]and located in the Illumina Human Body Map data 
(Figure 10). Cuffdiff, isoform t tests, and a linear model interaction term that 
incorporated disease and splice junction reads were tested on the positive 
control. The linear model that modeled how reads overlapped splice junctions 
was able to successfully identify the MEF2D gene as being significantly 
differentially spliced (the interaction term had a p < 0.02). Cuffdiff did not identify 
this positive control as differentially spliced, so that is why I decided to use the 
interaction term model.  
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Figure 9: An example of the expression discrepancies in Cufflinks/Cuffdiff. The 
top plot displays the Cuffdiff estimated phenotype-specific expression with confidence 
bars for the control and ILD samples being examined in two transcripts from the 
same gene. This is an example that Cuffdiff assigned as being significant. The 
bottom plot shows the Cufflinks estimated sample-specific expression level. Except 
for two outliers, all the samples show almost no expression in both of the transcripts, 
yet this is an example of gene that is considered differentially spliced by Cuffdiff. 
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3.1.3. Differential splicing analysis in emphysema and IPF identifies p53 
associated NUMB and PDGFA 
We have identified disease-associated alternative splicing events using an 
interaction term linear model. This analysis primarily identified genes with 
 
Figure 10: An example of tissue specific alternative splicing in Illumina Human 
Body Map Data in the gene MEF2D. An IGV wiggle plot of the mutually exclusive 
exons that are differentially spliced between brain and muscle shows that left exon is 
only ever expressed in thyroid, muscle, and heard tissue, whereas it is not expressed 
in the breast, brain, and adrenal samples. Muscle and Brain are emboldened 
because they are the two tissues where this case of alternative splicing was first 
identified in mouse samples [2]. 
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cassette exon skipping or inclusion events. We identified one gene in 
emphysema versus control samples and 27 genes in IPF versus control samples 
that were significant for the intereaction term between splice junctions and 
disease (q-value < 0.25) compared to controls (Table 4).  
 
 
Considering the heterogeneity of disease tissue samples and the large number of 
splice junctions could leave us underpowered to detect significant alternative 
splicing, we decided to relax the significant value (p-value < 0.01) in order to 
Table 4: Genes that were significant for the interaction between splice 
junctions and disease (q < 0.25). 
 
IPF vs. Control COPD/emphysema vs.s Control 
VCL FRY 
SYNE2  
MYLK  
FRY  
TNS1  
CEACAM1  
AC013461.1  
FAM65B  
VEGFA  
EPB41L5  
MUC5B  
KIAA1217  
MLLT4  
NUMB  
ARMC9  
SCEL  
RGS3  
WARS  
TPM1  
HPS3  
HNRNPF  
HOPX  
PDGFA  
CTNND1  
SGMS1  
AGER  
CES4  
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identify a set of alternative splicing events shared in both diseases, as these 
were less likely to be affected by a change in cell type content, given the 
differences between IPF and COPD. We also subset down to the genes with 
splice junctions that displayed switching expression associated with disease (i.e. 
at least one splice junction was downregulated with disease and one splice 
junction was upregulated with disease, this step specifically eliminated FRY). 
Two genes, PDGFA  and NUMB, (Figure  11a and 11b, respectively) appeared 
to show a significant concordant change in isoform proportions in both COPD 
with emphysema and IPF samples compared to control. By exploring the 
disease-associated splicing evens that were concordant across samples, we 
inferred that we could gain a better understanding of how the lung could be 
responding to chronic lung diseases while also limiting the impact that cell type 
changes were the cause of the changes in alternative splicing. 
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Figure 11. Box plots of significant splice junctions in PDGFA and NUMB. The 
structure of the two isoforms for both PDGFA and NUMB are shown in a) and b), 
respectively. PDGFA (a) isoform 001’s splice junction is upregulated in both 
COPD/emphysema and IPF, though the change in IPF is not as strong as in 
emphysema. Isoform 002’s splice junctions, accounting for inclusion of the cassette 
exon, are both down-regulated in chronic lung disease, though more so in IPF. 
NUMB (b) shows the reverse behavior, with isoform 203, missing the cassette exon, 
being downregulated, and the isoform 202 being not changing or being upregulated 
in emphysema and ipf, respectively.  
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In PDGFA, there was exclusion of an exon among both IPF and emphysema 
samples compared to normal histology controls. Specifically, while all samples 
express both isoforms of PDGFA, there was one splice junction supporting 
PDGFA isoform 001 that was increased and two splice junctions supporting 
PDGFA isoform 002 that were decreased in the disease samples compared to 
control (Figure 11a) and this is reflected in coverage plots (Figure 12a). 
Oppositely, in NUMB, there is preferential inclusion of an exon among both IPF 
and emphysema samples compared to control. There was a difference in ratios 
of isoform 203 and isoform 202 (contains extra exon 9) observed by changes in 
expression of one splice junction versus two splice junctions, respectively 
(Figure 11b). While the NUMB coverage plots are more subtle, there is a 
significant change (p < 0.01) in the proportions of these two isoforms reflected in 
the ratio of reads mapping to the genomic regions spanning exon 8 and exon 9 in 
Figure 12b.   
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In the differential gene expression analysis (performed by my colleague Rebecca 
Kusko) of IPF and emphysema (data not shown), one of the pathways that was 
 
Figure 12. Coverage plots of PDGFA and NUMB. These are coverage plots that 
show the interquartile range (lighter shading) of the samples from each phenotype as 
well as highlighting the mean (darker line). In (a), PDGFA’s exon expression shows a 
change from having a balance between the two exons in the box to a decrease of the 
relative expression of the cassette exon compared to the constitutive exon in 
emphysema and IPF. The change is  subtler in NUMB, where we see an increase in 
the cassette exon in IPF and COPD, though the larger change is that the isoform not 
expressing the cassette exon decreases in chronic lung disease (see Figure 11b), 
and this is not easily displayed in wiggle plots.
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enriched in differentially expressed genes in both IPF and emphysema was the 
p53 pathway. To see if there was any relationship between the two overlapping 
cases of alternative splicing, we ranked DE genes by their correlation to a ratio of 
the expression of the PDGFA splice junctions. Using this ranked gene list, we 
performed GSEA and identified the p53 hypoxia pathway as being significantly 
enriched (GSEA q-value < 0.05). We also took the list of p53 significant genes 
that were differentially expressed in emphysema and a list of p53 genes 
differentially expressed in IPF and saw that there was significant correlation of 
the individual PDGFA isoform ratios with 14 of the 21 differentially expressed p53 
genes in emphysema and 21 of the 29 IPF DE p53 genes (q < 0.25).  
 
 
 
Table 5: Demographics of independent cohort from LGRC 
 ILD COPD Control 
# of samples 77 34 82 
Age 64.4 ± 8.7 60.6 ± 9.5 63.8 ± 11.9 
Sex 54 M, 23 F 15 M, 19 F 35 M, 47 F 
Race 
69 CAU, 2 AFA,  
2 ASN, 1 OTH (3) 
33 CAU, 1 AFA 76 CAU, 1 HIS,  
1 AFA, 3 ASN,  
1 OTH 
Smoking status 
2 Current,  
42 Former,  
29 Never (4) 
2 Current,  
32 Former 
1 Current,  
43 Former,  
29 Never (9) 
Pack years 24 ± 18 (33) 51 ± 27 37 ± 32 (38) 
% DLCO 50 ± 17 (10) 36 ± 14 (2) 84 ± 15 (9) 
FEV1% predicted 74.5 ± 14.3 (51) 31.6 ± 12.7 (4) 100.0 ± 13.5 (24) 
% emphysema 0.9 ± 1.6 (63) 36.6 ± 9.9 (21) 0.6 ± 0.9 (71) 
 (Numbers in parenthesis are missing values) 
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The shared disease-associated alterative splicing event, PDGFA, was first 
validated by qRT-PCR (Figure 13) in a small subset of tissue samples (control n 
= 6, IPF n = 5, emphysema n = 5). For further validation, we used a different 
technology, nanostring [105,106], which allowed us to validate across a majority 
of the original cohort (subset down to n=52 samples instead of all 58 from the 
three phenotypes due to lack of extra mRNA for validation) as well as an 
additional independent cohort of samples (n=193) from the LGRC, though ones 
with less distinct phenotypes (Table 5). The nanostring results on the same 
subset of “pure” phenotype samples (n=52) validated that PDGFA isoform 001 
was upregulated in emphysema versus control samples and unchanged in IPF 
versus control samples. PDGFA isoform 002 was validated to be down-regulated 
in both IPF and emphysema samples versus control. This verifies that the 
isoform proportions of PDGFA are significantly different between disease and 
control samples in the original cohort (Figure 14).  
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Figure 13. Validation of PDGFA alternative splicing with qRT-PCR. Bars that 
show 3D emboss signify that the result is significantly differentially expressed 
compared to the control samples (p < 0.05). The top row of plots show the 5 vs. 5 
control versus emphysema PCR run with relative expression showing the differences 
between the changes in isoform, validating what was seen in the box plots of the 
RNA-seq data. The bottom row of plots confirmed the change in differential splicing of 
the IPF isoforms. PDGFA3 was the name given to the common primer that measured 
expression of both isoforms by measuring a constitutive exon. 
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The Nanostring results across 193 lung tissue samples validated that PDGFA is 
differentially spliced in the more general COPD samples compared to control (p-
value < 0.05) (Figure 15a). On the other hand, when moving to a more general 
set of ILD samples that are not as distinct a phenotype as the original IPF 
samples, PDGFA appears to be significantly differentially expressed rather than 
differentially spliced, showing that the differential splicing is more specific to IPF 
 
 
 
Figure 14. Validation of NUMB and PDGFA isoforms with nanostring in original 
samples (n=52). The 3D embossed bars signify differential expression from control 
at p < 0.05. These bar plots display the mean and the standard error of the 
normalized number of times a transcript was counted by the nanostring method. a) 
PDGFA-001, the isoform missing the cassette exon, is upregulated in the 
emphysema samples and trends upwards, but not significantly, in the IPF samples, 
mirroring the RNA-seq data for these same samples as seen in Figure 11a. PDGFA-
002, containing the cassette exon, is significantly down-regulated in both chronic lung 
diseases compare to control tissues. b) NUMB-202, containing the cassette exon, is 
upregulated in both emphysema and IPF samples, whereas NUMB-203, which skips 
the cassette exon, is significantly down-regulated in IPF and trends downward in 
emphysema, mirroring the RNA-seq data as seen in Figure 11b. 
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samples than to the ILD samples. The Nanostring results also confirmed that the 
NUMB isoform 203 was significantly down-regulated across IPF versus control 
samples, whereas the NUMB isoform 202 was significantly up-regulated in IPF 
samples (Figure 15b). Unfortunately, NUMB did not validate when expanding to 
the larger set of more general COPD samples, perhaps because these COPD 
samples have a broader range of percent emphysema compared to the 19 
emphysema samples analyzed using RNA-seq that had a percent emphysema > 
30%). We also validated SCEL, an IPF specific case of alternative splicing (see 
Table 4), as being differentially spliced via both qRTPCR and nanostring, 
however we did not explore this gene further (data not shown). 
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3.3. Discussion 
This chapter presents two clinically different diseases being profiled in parallel for 
alternative splicing. Analysis of the sequenced RNA reads that overlap known 
splice junctions allowed us to identify disease associated changes in alternative 
 
 
 
Figure 15. Validation of NUMB and PDGFA isoforms with nanostring in 
independent cohort of LGRC samples (n=193). The 3D embossed bars signify 
differential expression from control at p < 0.05. These bar plots display the mean and 
the standard error of the normalized number of times a transcript was counted by the 
nanostring method. Also note these samples represent general clinical categories 
COPD and ILD rather than the more specific COPD/emphysema and IPF phenotypes 
used for the original set of samples. a) PDGFA’s differential splicing is confirmed in a 
larger set of COPD independent samples using nanostring. However, the ILD 
samples, while significant, are significant in a pattern that shows differential in ILD 
rather than differential splicing. PDGFA appears to be down-regulated across in ILD, 
though this could be due to looking at general ILD samples rather than more specific 
IPF samples. b) In the larger, more general set of COPD samples, NUMB does not 
appear to be differentially spliced (though one of the transcripts, NUMB-203, trends 
downwards). The ILD samples are confirmed as being differentially spliced similar to 
the IPF samples in Figure 14b.  
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splicing proportions. This analysis revealed that, like differential expression, there 
were more genes identified as differentially spliced (DS) in IPF versus control 
than in emphysema versus control.  
 
A look at concordant alternative splicing between IPF and emphysema identified 
PDGFA and p53-associated NUMB as genes that were differentially spliced in 
both disease groups and that the change in isoform expression was in similar 
directions. NUMB has four primary isoforms that occur from the alternative 
splicing of two regions a phosphotyrosine-binding domain (PTB) and a proline-
rich region (PRR) which is a SH3-binding domain. In IPF and emphysema, we 
see evidence for a change in the alternative splicing of the PRR based on the 
splice junctions that distinguish between the isoforms that contain a 144 nt (48 
amino acid) insert in the PRR and the isoforms that do not include that insert in 
the PRR. In both IPF and emphysema we see an upregulation in the expression 
of the NUMB isoform with the longer PRR and a relative decrease in the 
expression of splice junctions that support the NUMB isoform with the shorter 
PRR. This result is of particular interest because of its relation to the p53 
pathway. The NUMB protein is known to bind to both TP53 and MDM2 
separately and may potentially form a triplex with TP53 and MDM2, stabilizing 
and preventing TP53 from being degraded [107-109]. How the observed splicing 
event affects the role of NUMB in the p53 pathway remains to be characterized 
at the bench and is an area of potential future study.   
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PDGFA has two primary transcript products (Ensembl isoforms PDGFA-001 and 
PDGFA-002) that are 196 and 211 amino acids long, respectively [110,111]. The 
longer (PDGFA-002) version contains exon 6 and appears to be down-regulated 
in IPF and emphysema, while the shorter (PDGFA-001) version does not and 
tends to not change in expression or is increased in chronic lung disease. The 
extra exon is transcribed into a retention domain composed of a 15 amino acid 
long carboxy-terminus that gets ensnared by binding to heparin sulfate in the 
extra-cellular matrix, and this prevents this isoform from diffusing away from the 
cell; whereas the shorter isoform is able to diffuse and signal other cells [112-
117]. While there is limited understanding how the individual isoforms may play a 
role in the p53/hypoxia pathway, Mizuno, Shiro et al., 2010, [118] have shown 
that, in mice lung tissue with hypoxic exposure, PDGFA expression has been 
shown to increase. Changes in PDGFA expression have also been identified in 
rat lungs with hypoxic pulmonary hypertension [119]. Furthermore there is also a 
relationship between MUC1 and regulation of p53/hypoxia gene HIF1alpha in 
human lung epithelial cell lines and MUC1 itself has been shown to regulate 
PDGFA expression [120,121] and PDGFA has been shown to correlate with 
HIF1A [122].  
 
In the work done by Rebecca Kusko on the known gene expression changes in 
IPF and COPD, we’ve also shown that there is a significant enrichment of genes 
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associated with these p53 / hypoxia pathway in a list of genes whose expression 
also correlates significantly with the ratio of measurements of the two different 
isoforms of PDGFA and this further evidence that this overlapping alternatively 
spliced gene in IPF and COPD might also be related to the p53 hypoxia pathway 
While this suggests a relationship that may affect the p53/hypoxia pathway, like 
NUMB, the details of how the two isoforms function to affect the p53/hypoxia 
pathway are unknown and a potential area of future study. That these two genes 
are alternatively spliced in both diseases supports that these splicing changes 
are less likely to be cell-type specific. Overall, the fact that the two validated 
overlapping cases of alternative splicing in both IPF and COPD show evidence of 
a relationship with the p53/hypoxia pathway gives support of the convergent role 
the p53 pathway may play in these two diseases. 
 
3.4. Methods 
3.4.1. Alternative splicing linear model 
First, Tophat v1.2 was run, allowing only known junctions from the Ensembl 59 
annotation to be identified. The junction.bed output file containing only the 
number of reads mapping to splice junctions was used to collect the number of 
reads that span each reported splice junction for each lung tissue sample 
sequenced. Splice junction RPM values  (number of reads spanning a splice 
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junction / number of reads spanning all splice junctions in a sample) were used to 
filter out splice junctions expressed too lowly (1 RPM or less).   
 
A linear model with an interaction term was run, using the RPM of reads 
spanning each splice junction: 
 
log2 (NSJRipq) ~ 
 βintercept + βjunctionXjunction + βdiseaseXdisease  +  βinteraction(Xjunction* Xdisease) + εi 
 
In that model, the log2 normalized splice junction reads (NSJR) of the ith splice 
junction for gene p in patient sample q was used. NSJR was a function of (1) the 
splice junction specific main effect (βjunction) that accounted for the expression 
differences between the patient tissue samples of each of the splice junctions 
labeled 1,2,3, etc. (Xjunction) within gene p, (2) the disease specific main effect 
(βdisease) that accounted for the expression differences of the diseases being 
compared labeled 0 for control tissue samples and 1 for disease (Xdisease), and 
(3) for an interaction main effect between splice junction and disease (βinteraction). 
By identifying cases where the interaction effect was significant and individual 
significant coefficient making up that interaction effect showed a switching in fold 
change direction between diseases and splice junctions (at least one positive 
and one negative t statistic), we could subset down to a set of potential cases of 
genes differential isoform usage associated with disease.   
 
61 
 
 
Genes of interest were identified and further subset by visually examining box 
plots of all of the splice junctions. Splice junction with case/control interaction 
terms that contributed significantly in the model were the ones that were 
visualized. Switching behavior as well as the structure of the significant splice 
junctions was examined to identify potential alternative splicing between the 
disease and control sample.  
 
3.4.2. Validating Alternative Splicing using quantitative real time PCR 
Quantitative RT-PCR analysis was used to confirm the differential expression of 
alternatively spliced transcripts. Primer sequences for alternatively spliced 
transcripts of two genes (PDGFA, SCEL) were designed with PRIMER 
EXPRESS software (Applied Biosystems, Foster City, CA). RNA samples (500 
ng of residual RNA from the samples used in the mRNA sequencing) were 
treated with TURBO DNA-free (Ambion, Foster City, CA), according to the 
manufacturer's protocol, to remove possible contaminating genomic DNA. Total 
RNA was reverse-transcribed by using random hexamers (Applied Biosystems) 
and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). The resulting 
first-strand cDNA was diluted with nuclease-free water (Ambion) to 4 ng/μl. PCR 
amplification mixtures (25 μl) contained 20 ng of template cDNA, 12.5 μl of 2× 
SYBR Green PCR master mix (Applied Biosystems) and 600 nM forward and 
reverse primers. Forty cycles of amplification and data acquisition were carried 
out in StepOnePlus Real-Time PCR systems (Applied Biosystems). Threshold 
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determinations were automatically performed by StepOne Software (version 
2.2.2; Applied Biosystems) for each reaction. All real-time PCR experiments were 
carried out in triplicate on each sample (mean of the triplicate shown in qRT-PCR 
figure). Relative gene expression levels were calculated using the comparative 
CT method [123]. 
Primer Sequences for PCR Validation: 
>PDGFA1-F (primer for PDGFA-002, contains extra exon) 
CGACCACAAGCCTGAATCC 
>PDGFA1-R (primer for PDGFA-002, contains extra exon) 
TTTACCTGACTCCCTAGGCCTTC 
>PDGFA2-F (primer for PDGFA-001, missing exon) 
GAAGAGGACACGGATGTGAGG 
>PDGFA2-R (primer for PDGFA-001, missing exon) 
TGTCCCAGGAAAGGGCTG 
>PDGFA3-F (overlaps exon shared by both PDGFA isoforms) 
ACTATGTACGGTGCTTTATTGCCA 
>PDGFA3-R (overlaps exon shared by both PDGFA isoforms) 
TTCACGGAGGAGAACAAAGACC 
>SCEL201-F 
TGACACTTTGGACAGGAGCATG 
>SCEL201-R 
GCAACTTTGTTACTTCCAGTGATCTAA 
>SCEL001-F 
TCTGATGACACTTTGGACAGGATCT 
>SCEL001-R 
TGTTTTAGCAGCATCATTTCTGTCT 
>SCELcomm-F 
GATCACTGGAAGTAACAAAGTTGCA 
>SCELcomm-R 
TGTTGGCATTCAATGAACCG 
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3.4.3. Validating Alternative Splicing using Nanostring 
500 ng of total RNA was hybridized to a 3` biotinylated capture probe and a 
5`reporter probe tagged to a fluorescent barcode. Following overnight 
hybridization at 65°C, the samples were transferred to the nCounter Prep Station 
where excess probes were washed out, and the probe-RNA complexes were 
bound and immobilized on the streptavidin-coated cartridges. The cartridges 
were scanned in the nCounter Digital Analyzer using 1155 fields of vision. Each 
RNA of interest is identified by the unique color code generated from the order of 
fluorescent segments on the reporter probe. The data was normalized using 
GUSB as the housekeeping gene. Nanostring is essentially a hybridization 
method designed for high-throughput validation but without the amplification 
steps of PCR [105,106].   
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4. DEVELOPING AND IMPROVING A PIPELINE TO ASSEMBLE 
THE NON-MALIGNANT CHRONIC LUNG DISEASE TISSUE 
TRANSCRIPTOME 
Unlike hybridization based methods such as microarrays, the true advantage of 
RNA-sequencing is not that we can interrogate known genes and alternative 
splicing events, but that we can also measure the mRNA sequences of 
transcripts that have not been previously annotated. The process of taking 
millions of Illumina short reads composing billions of sequenced nucleotides, and 
reassembling an RNA transcriptome from those reads is not a simple or apparent 
process. Therefore, in this chapter, I will present an overview of steps and 
processes, inspired by the works of Prensner JR, et al. [124] and Cabili MN, et al. 
[66], that take the LGRC lung tissue samples from short reads all the way to a 
final, improved transcriptome reassembly. These steps will include alignment, 
sample quality analysis and filtering, splice junction filtering, reference guided 
transcript assembly, assembly filtering, novel loci identification, and loci 
classification (Figure 16).  
 
In this chapter, we’ve expanded to a larger set of 281 samples from LGRC 
(Table 6). Patient clinical information, pulmonary functions, demographics, 
imaging results and pathology and clinical diagnoses were available. Exploiting a 
larger number of lung tissue samples gives us more power to detect lowly 
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expressed features as well as a greater ability to look at how genomic features 
behave across these samples.  
 
 
Table 6: Demographics of the 281 lung tissue samples from the LGRC 
 ILD COPD Control 
# of samples 103 130 48 
Age 60.4 ± 11.4 64.0 ± 10.4 63.2 ± 12.2 
Sex 60 M, 43 F 74 M, 56 F 29 M, 19 F 
Race 
90 CAU, 1 HIS,  
7 AFA, 1 ASN,  
2 NAM, 1 OTH (1) 
126 CAU, 4 AFA 46 CAU, 2 AFA 
Smoking status 
4 Current, 68 
Former, 28 Never 
(3) 
5 Current, 118 
Former, 5 Never 
(2) 
1 Current, 30 
Former, 14 Never (3) 
Pack years 25 ± 19 (31) 54 ± 35 (7) 44 ± 41 (17) 
% DLCO 47 ± 18 (11) 56 ± 23 (17) 82 ± 17 (4) 
FEV1% predicted 74.1 ± 16.6 (76) 55.8 ± 25.4 (21) 97.3 ± 8.7 (14) 
% emphysema 0.9 ± 1.6 (51) 36.6 ± 9.9 (17) 0.6 ± 0.9 (24) 
 (Numbers in parenthesis are missing values) 
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4.1. Sample overview 
While utilizing the same 87 samples from the previous chapters, our group also 
sequenced another 194 samples for a total of 281 samples. Overall, 95 of these 
samples were sequenced at 75 bp paired end on a GAIIx machine in a single 
plex fashion. However, one of the improvements to our process has been 
acquiring an Illumina HiSeq 2000 machine. This allowed us to sequence many 
more samples per flow cell using a multiplex barcoding protocol. By using the 
multiplexing protocol, we could sequence 32 samples per flow cell and obtain 
 
 
Figure 16. Overview of the steps performed in order to assemble and improve 
the lung tissue transcriptome.  
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anywhere from 40-60 million paired ends on average. This significantly sped up 
our RNA-seq data acquisition, and gave us access to a further 186 sequenced 
samples of lung tissue. On average, the total number of paired end reads 
sequenced per sample was approximately 36 million with a standard deviation of 
9.5 million reads. At least 10 billion paired end short reads have been sequenced 
from the LGRC project in total.  
 
4.2. Initial alignments with Tophat 
In this section, we utilize a more recent Tophat version, Tophat v 2.0.4, which 
has been updated to run the Bowtie2 algorithm [41]. To run tophat on our 
samples, we first did an alignment with tophat where we estimated the insert size 
parameter (the mean and standard deviation of distance/overlap in bp between 
two properly paired reads, either the space in between the two reads or, 
depending on library size and length of the reads, the overlap). Our library 
fragment size of the short reads for both the GAIIx and the HiSeq was estimated 
to be around 200 bp in length. Therefore, with the GAIIx samples (n=95), which 
were run as 75 bp paired ends, we’d expect the average insert size to be 50 bp. 
We estimated a large standard deviation of 100 for this to ensure that reads 
could be successfully aligned. For the 99 bp paired end reads fron the HiSeq 
samples (n=186), we estimated the insert length to be -25 (25 bp overlap on 
average) with a standard deviation of 100. Tophat v2.0.4 was run with this as the 
initial alignment. 
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In order to get a better set of alignments, we wanted to pick an optimum 
parameter for the insert length mean and sd. To do this, we used the first Tophat 
run and estimated the empirical RNA-seq insert sizes (the average distance in bp 
between two properly paired reads) using one of the steps of the tool MISO 
[125]. For each sample, the insert length is computed through MISO’s insert 
length tool by 1) identifying a list of constitutive exons > 1000 bp from an 
annotation file (Ensembl release 64 [44]), 2) selecting all the paired end reads 
within each sample that align both first and second pairs to the same large exon 
(usually around 2,000,000 reads total), and 3) estimating the insert length mean 
and standard deviation from those paired ends. We then use the mean and 1.5 * 
the standard deviation calculated for each sample and run Tophat a second time 
(the standard deviation * 1.5 is still usually smaller than the 100 standard 
deviation used originally, so tophat runs faster, and still checks for a wide range 
of differences in insert lengths).  
 
Parameters used for Tophat v2.0.4 empiric run per sample: 
 --library-type fr-unstranded 
 -r mean.generated.by.miso.tool 
 -- mate-std-dev sd.generated.by.miso.tool * 1.5 
 --splice-mismatches 0 
 --read-mismatches 2 
69 
 
 
 --max-multihits 20 
An average of 91% ± 9% of the total reads are aligned to the hg19 human 
genome. Of those aligned reads, 90% ± 7% of the reads aligned as paired end 
and within the paired end reads 88% ± 5% align as properly paired reads. By and 
large these numbers are a sign of good quality samples, however, in the next 
section we do filter out a set of samples that have lower than average quality. 
 
4.3. Quality control using sequencing and alignment statistics 
Once the previous Tophat alignment is finished, the FastQC program [76] and 
the samtools [126] flagstat command are run on the FastQ (contains the 
sequenced reads and the per base phred quality score [127]) and Tophat bam 
files, respectively. FastQC returns a set of statistics based on the sequenced 
reads themselves, specifically the base sequence quality phred score is of 
interest. The score is assigned per base, and it is the -10*log10(probability) that a 
base is likely to be incorrectly called by the sequencer. In Figure 17, three 
examples of a per base sequence quality plot from FastQC are shown to 
highlight a good GAIIx sequencing run, a good HiSeq sequencing run, and a low 
quality HiSeq sequencing run. 
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Figure 17. Per base quality plots from FastQC. These three plots are examples of 
per base quality plots. Each base or sequences of bases shows a box and whisker 
plot, which shows the –10log10(p) phred score. The yellow boxes represent the 
interquartile range for a specific bp position, and the tick marks represent the max 
and min phred scores per base. The red tick marks represent the median phred 
quality score, whereas the blue line represents the mean. (a) This FastQC per base 
quality plot displays an example of a very high quality GAIIx sequencing run. The 
minimum median phred score doesn’t drop below 38, which is equivalent to a p that 
the base is incorrect of ~0.000159. (b) This is an example of a high quality HiSeq 
FastQC run, and in this case, the plot groups together some of the base positions to 
save space. The dip at the beginning of the plot is typical in HiSeq runs becase the 
base caller uses information about previous bases to correct latter base call scores. It 
takes up to nine or ten cycles for the base calls to become very confident. This is a 
very good run with the minimum median phred score never dropping below 34. (c) 
Finally this is an example of a poor quality run. The base calls position quality get 
very low towards the end of the reads, as the minimum median base quality phred 
score actually goes as low as 2, which means that the base has a p of ~0.63 of being 
incorrect. 
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Samtools flagstat command parses through an aligned bam file from the tophat 
run and returns specific information about the alignment, specifically: the number 
of reads in the bam file, the number of duplicates, the number of reads that 
mapped, the number of the first end of the reads that mapped, the number of the 
second end of the reads that mapped, the number of reads that mapped as 
proper pairs, the number of reads that aligned as paired ends (not necessarily 
proper), the number of reads that aligned as singletons, and the number of reads 
with a paired end mapping to a different chromosome. I used both the FastQC 
per base quality phred score and the percent of reads that aligned from Samtools 
as metrics for filtering to higher quality samples (Figure 18 and 19, respectively). 
 
 
 
Figure 18: The Minimum( Median( Phred score per position ) in the 281 RNA-
seq samples (19 sequencing runs total). Generally the minimum median phred 
score across all the positions within a sample did not drop below 25-30 (p = 0.001), 
though, the 16th LGRC run had particularly low scores, with the minimum median 
phred dipping down to 2 in most of those samples.
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Based on the plots in Figures 18 and 19, I chose the following quality metrics to 
filter out LGRC samples: 
1. If at any position in a sample the median phred score dropped 
below 25, that sample was removed from further downstream 
analysis 
2. If a sample had fewer than 75% of its total reads aligning to the 
hg19 human genome, it was removed 
This lead to the removal of 44 samples (32 of which were from LGRC run 16) 
from the analysis. From this point on, we utilized 237 good quality samples. 
 
 
Figure 19: Percent of reads that aligned across 281 samples. In a majority of the 
samples almost 75% or more of all of the sequenced reads align to the human hg19 
genome. However, there are some cases where far fewer reads align than that, and, 
like in Figure 18, the LGRC run was particularly low quality with most of the samples 
aligning with less than 75% of the total reads sequenced.
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4.4 Filtering low quality splice junctions from Tophat and realigning 
In order to get an idea of how well Tophat performs at identifying splice junctions, 
I ran Tophat once more on the samples, but this time forced them to align just to 
the genes and splice junctions that are annotated in the Ensembl 64 annotation.  
This required the addition of the following parameters: 
-G /path.to/ensembl64.gtf 
--no-novel-juncs 
 
By running with these parameters, tophat will only align to the splice junctions 
found in the Ensembl 64 annotation. I was then able to compare the number of 
splice junctions found in Ensembl, the number of splice junctions Tophat aligned 
to when forced to align to Ensembl, and the number of Ensembl and de novo 
splice junctions identified when running Tophat in its de novo splice junction 
finding mode across all 237 samples. (Table 8). 
 
 
Table 7: Tophat splice junctions 
 Total # of splice 
junctions 
# of Ensembl 
64 splice 
junctions 
with aligned 
reads 
# of de novo 
junctions with 
aligned reads 
Ensembl 64 325,469 
  
Tophat  
(Ensembl only) 
285,082 285,082 0 
Tophat  
(de novo) 
1,707,252 262,768 1,444,484 
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As can be seen in Table 8, the number of annotated junctions aligned to by very 
similar regardless of whether Tophat is forced to align to a known set of 
annotated splice junctions or allowed to identify splice junctions algorithmically 
without any set annotation. However, the number of de novo splice junctions it 
identified across the 237 samples was nearly 5-6 times as many as canonical 
splice junctions. This appeared to be an excessive number of splice junctions, so 
I wanted to explore the behavior of these splice junctions and see how often 
each individual Tophat run identified a specific splice junction (Figure 20). The 
comparison illustrates that there are potentially a lot of spurious splice junctions 
identified by Tophat when run de novo across many samples. I identified that 
there were 726,310 single sample splice junctions (SSSJ) which make 42.5% of 
the total 1,707,252 splice junctions identified by Tophat, and over 1 million splice 
junctions were found in 3 or less samples.  
 
Only about 8,000 of the SSSJ are junctions annotated by Ensembl; the rest of 
the SSSJ were all novel junctions. Overall, 96% of the SSSJ were expressed 
with RPM < 0.5, whereas only 0.001% of splice junctions found across all 237 
samples had a median RPM < 1. In order to be conservative, I decided to remove 
only the novel SSSJ. The remaining 1,000,000 splice junctions that were found 2 
or more samples were kept. Tophat was then rerun, but forced only to align to 
the splice junctions found in 1,000,000 samples. By doing this, reads that align to 
this spurious junctions will no longer be aligned or will align to a different place in 
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the genome. This was done because Cufflinks, the software used to assemble 
the transcriptome, works to identify a parsimonious transcriptome that accounts 
for all aligned reads. Therefore, by the removal of these spurious junctions and 
reads, we’ve removed spurious transcripts that would affect the structure of the 
final assembly. 
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Figure 20: Known and novel splice junction behavior across 237 LGRC 
samples. This plot displays how often a splice junction is identified by Tophat 
across the 237 LGRC samples. The plots are ordered starting with those splice 
junctions only found in a single sample and then increasing from left to right until 
reaching the splice junctions that have reads aligning to them in every sample. a) 
These are the 285,082 Ensembl splice junctions identified in at least one LGRC 
sample when forced to align just to Ensembl splice junctions and observed to have 
reads aligned in at least one LGRC sample. Notice that there are very few splice 
junctions found in just a single LGRC sample. b) The 1,707,252 splice junctions 
identified by the de novo Tophat run (including 262,768 canonical Ensembl splice 
junctions) and observed to have reads aligned in at least a single sample. Note the 
much larger tail in this plot, illustrating the huge numbers of splice junctions only 
found in a single sample. 
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4.5 Download reference annotations and create union annotation files 
Using the UCSC Genome Browser’s Table Browser [45], the following 
annotations were downloaded: UCSC (includes Refseq [128] and Genbank [129] 
annotation) and Vega gene [130]. We were already using the Ensembl release 
64 annotation in the previous step, and this was downloaded from the Ensembl 
website. We also downloaded the AceView [131], Broad LincRNA catalogue, and 
Broad Transcripts of Uncertain Coding Potential (TUCP) annotations [66,132].  
 
I wanted to utilize the all of the information from the UCSC, Ensembl, and Vega 
reference transcriptome annotations when performing the Cufflinks reference 
annotation-based transcript assembly, however, Cufflinks/Cuffmerge only utilizes 
a single gtf annotation file as the reference when this step is performed. As both 
AceView and the Broad LincRNA have less well annotated transcripts and loci, 
we will use them for comparison in a later step with our assembly, but will not be 
using them within Cufflinks in the next step. 
 
Therefore, I took advantage of the Cufflinks program Cuffcompare to make a 
union gtf file of these three annotations (see Cufflinks manual at 
http://cufflinks.cbcb.umd.edu/manual.html). Cuffcompare is a program that 
compares multiple sets of annotations to a reference set and adds in certain 
Cufflinks specific information. It can be used as a “union” function for combining 
multiple annotations together. To do so, one has to take advantage of the -G 
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parameter that tells Cufflinks that the gtf file is not output from Cufflinks itself, and 
one can choose to use the -C parameter to keep so-called “contained in” 
transcripts in the gtf files (basically if a transcript has the same intronic structure 
as another transcript, but is shorter, it will be merged together if you do not use -
C). In our case, I wanted to have a simpler annotation file and did not use the -C 
parameter. 
 
Here is an example of what the cuffcompare command would I used looks like: 
cuffcompare 
-r ensemble.64.mod.gtf \ 
-o output.name \ 
-s dir.of.hg19.chr.fasta.files \ 
-G \ # Tells Cuffcompare that these are not cufflinks gtf files but more general gtf files 
-V \ #verbose mode 
ensemble.64.mod.gtf UCSC.gtf 
vegaGene.gtf 
 
Two problems with using cuffcompare for this step: 1) that all the transcript and 
loci/gene ids from the original files are given new unique identifiers, and the old 
transcript ids are stored as “oId” in the union annotation output gtf file and 2) the 
CDS entries in the original GTF files are not retained. My pipeline has a script 
that corrects this issue and restores the original transcript ids and adds back 
CDS entries from the original annotation gtf file annotation files if the transcript 
they reference remains in the output union file.  
 
79 
 
 
4.6. Run Cufflinks and Cuffmerge to create initial assembly 
In the next step, I ran a more recent version of Cufflinks, Cufflinks v2.0.2 
transcript assembly algorithm on each of the samples individually and then 
Cuffmerge on the the individual results of cufflinks . This was run using the 
reference annotation-based transcript assembly mode and used the union 
annotation from the previous step.  
 
I also followed the steps in [133] to get a mask gtf file with the repetitive and 
abundant elements of the genome such as rRNA , tRNA, and other genomic 
repeats listed. I combined this with the entries from ensemble 64 for tRNA, rRNA, 
and mitochondrial transcripts to create a mask file used in the Cufflinks run.  
 
Here are the parameters we used in to run the individual Cufflinks runs (some of 
these parameters lead to much longer run times, but fewer regions of the 
genome are skipped and left unprocessed when done so): 
 
cufflinks \ 
--no-effective-length-correction \  # Turns off effective length 
correction, which I’ve found to 
inflate the final expression values 
for some loci that have no reads 
aligned to them in the raw data 
 
--max-bundle-frags 50000000 \ #  The maximum number of 
reads/fragments a locus may 
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have before being skipped by 
Cufflinks. Default is 1,000,000 
--total-hits-norm \ 
--small-anchor-fraction 0.08 \ # Requires that 8% of a read 
overlaps on at least one side of a 
splice junction to be counted as 
expressed for that junction 
(similar to the default in Tophat) 
--max-bundle-length 5500000 \ # Maximum number of base pairs 
that a set of genes/loci that are 
calculated together can be 
-o output_name 
-g ensemble.64.annotation.gtf \  # Gtf file used for reference-
based assembly  
-M mask.file.gtf  # Directs cufflinks to ignore all 
reads that overlap with whatever 
is in the mask file 
 
-b hg19.fa # Runs bias correction algorithm 
to correct fragment biases [134]  
 -u \ 
--library-type fr-unstranded \ # Performs multi read correction 
-N \ # Performs quartile normalization 
[135] 
-L label.id # Sets output file prefix name 
tophat.alignedment.bam # The bam file being run 
 
 
Each of these runs produces a gtf file, which is then merged together using 
Cuffmerge. Cuffmerge works by converting the gtf file assembly structure into 
bam files, merges these bam files together, runs cufflinks again, and then runs 
the output from cufflinks in cuffcompare against the reference gtf given. This is 
the recommended way of getting an initial assembly of transcripts in a data 
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driven manner that accounts for all of the RNA-seq reads in the 237 samples 
[136] while still using a reference annotation to produce a better set of final gene 
models. We utilized the Ensembl, UCSC, and Vega union gtf produced in the 
previous section for this step.  
 
Cuffmerge was run with the following parameters: 
 
cuffmerge \ 
-g ensemble.ucsc.vega.combined.gtf \ # Runs cuffmerge in the 
reference annotation-
based transcript assembly 
mode 
 
---s folder.with.hg19.chromosome.fasta.files \  #Reference human 
genome fasta file 
Text.file.of.237.goodQC.gtf.files.txt 
 
The output of this step was the initial chronic lung disease transcriptome. This 
transcriptome contained 517,672 transcripts in total. In comparison, there are 
79,969 transcripts in UCSC, 169,257 in Ensembl, and 259,440 in AceView. 
Therefore, in the next step of the pipeline, we have to filter out spurious 
transcripts and loci. 
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4.7. Filtered and created a final assembly 
1) Filtered by structure: Based on the 200 bp library fragment size used by both 
the GAIIx and HiSeq sequencing runs in the 237 samples, we removed any 
transcripts with lengths < 200 bp. This was done because it would be unlikely 
that transcripts of this length or less would be well covered by an experiment with 
set to measure fragments of at least 200 bp. We also removed transcripts from 
the gtf assembly if they were single exon fragments that overlapped 75% or more 
of another, multi-exon transcript using BEDtools [137].  
 
One of the benefits of the cuffcompare/cuffmerge program is that each transcript 
in the chronic lung transcriptome assembly, both known and potentially novel, is 
compared to the reference union gtf and classified with specific class codes. 
These classes codes are listed in Table 9 and are directly quoted from the 
Cufflinks online manual 
(http://cufflinks.cbcb.umd.edu/manual.html#class_codes). We removed the 
transcripts in the assembly marked as e (removed by previous step, mostly), s , 
r, or p. In this filtering step, we went from approximately 72,000 loci containing 
527,000 transcripts down to about 60,000 loci and 495,000 transcripts. 
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2) Filtered by coverage: Next we wanted to filter the transcripts in the assembly 
by the amount of sequenced reads that aligned to them. The BEDTools 
multibamcov tool was applied in order to count how many reads overlapped each 
transcript in the current assembly per LGRC sample. Next, for each transcript, 
we calculated whether or not more than 25% of the samples had >1, >10, or >20 
reads per sample (Table 10). We chose to filter out transcripts in this section by 
looking at what numbers of annotated transcripts versus novel (class code: = 
versus j or u, see Table 9) transcripts were removed at each step. We wanted to 
remove as many spurious novel loci and transcripts as possible while not 
Table 8: Cuffcompare/Cuffmerge class codes comparing assembled transcripts 
to reference annotation 
 
Code Description 
= Complete match of intron chain 
c Contained 
j 
Potentially novel isoform (fragment): at least one splice 
junction is shared with a reference transcript 
e 
Single exon transfrag overlapping a reference exon 
and at least 10 bp of a reference intron, indicating a 
possible pre-mRNA fragment. 
i A transfrag falling entirely within a reference intron 
o Generic exonic overlap with a reference transcript 
p 
Possible polymerase run-on fragment (within 2Kbases 
of a reference transcript) 
r 
Repeat. Currently determined by looking at the soft-
masked reference sequence and applied to transcripts 
where at least 50% of the bases are lower case 
u Unknown, intergenic transcript 
x Exonic overlap with reference on the opposite strand 
s 
An intron of the transfrag overlaps a reference intron 
on the opposite strand (likely due to read mapping 
errors) 
 
84 
 
 
throwing out too many known transcripts and loci, and so removing transcripts 
that don’t have at least 10 reads in 25% of the LGRC samples seemed to be a 
good cutoff point to meet those needs.  
 
 
3) Filtered by removing redundancy: For the last step of the filtering process, we 
used Cuffcompare to remove transcripts “contained in” other transcripts within 
the final assembly. This is done by running cuffcompare on the gtf file of the 
assembly while also pointing to the assembly as a reference. This simplifies the 
overall assembly by removing transcripts that have the same intron boundaries 
but either different lengths or and fewer, but entirely overlapping exons within the 
same intron boundaries (Figure 21). 
Table 9: Filtering known and novel loci and transcripts by varying transcript 
coverage 
 
 "=" 
transcripts 
"j" 
transcripts 
"u" 
transcipts 
"=" 
loci 
"u" 
loci 
Initial assembly 262978 222625 20120 50261 17747 
Initial structural filter 242257 222618 19782 38372 17553 
Require per transcript 
25% of samples have 
>= 1 reads 
221578 221462 8325 26315 6130 
Require per transcript 
25% of samples have 
>= 10 reads 
204046 219328 4102 20529 2209 
Require per transcript 
25% of samples have 
>= 20 reads 
196061 216914 2911 18873 1293 
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Overview of final filtered assembly: Each of the filtering steps of this section are 
optional and there are gtf assemblies made at each step in the process. This 
means that, like the Broad LincRNA catalogue [132], users can choose from 
more or less stringent assemblies. Also, each assembly has been converted into 
BED format for use in programs like BEDTools or other programs that require 
BED files instead of GTF file formats. 
 
Overall, after performing these filtering steps, our final assembly went from 
containing 71,811 loci and 517,672 total transcripts to 26,631 loci and 370,228 
transcripts; a number similar to what is seen in AceView. 
 
 
Figure 21: Dummy example of how Cuffcompare can simplify the final 
assembly. Notice that transcripts with the same intronic structure, but differing 
exonic lengths are merged as well as single exon transcripts that are entirely 
contained by other exons. The single exon that does not overlap and would not fit 
with the intronic structure of the other transcripts remains.  
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4.8. Overlapped AceView and Broad LincRNA and TUCP annotations with 
final assembly 
One final enhancement to the final assembly was to add information to each 
transcript entry in the gtf indicating whether or not said transcript overlapped at 
all with transcripts in the AceView annotation, the Broad LincRNA catalogue, or 
the Broad TUCP annotation. We used BEDTools IntersectBed function and 
added this information to our final assembly.  
 
4.9. Identified novel loci 
A locus in our final assembly was considered novel if all of the transcripts from 
that locus did not overlap with either the UCSC, Ensembl 64, or Vega annotation 
(basically each transcript making up a locus had to be marked with the “u” class 
code, suggesting that it was completely unknown). A novel locus could still 
overlap with AceView and the Broad annotations, and in some cases they do and 
in others they do not, meaning that we find some of the same unclassified 
regions of expression as these other more experimentally-based annotations.  
Using this criteria, 1,855 loci out of the 26,631 loci in our final assembly are 
considered novel. An example of a novel locus and a display of all the 
information contained in the final assembly annotation gtf file is displayed in 
Figure 22. 
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4.10. Classified novel loci 
There were two steps of classification performed on these loci. The first 
classification was to identify which of the loci had single exon transcripts and 
which of the loci had multiple exon transcripts (some loci have both).  
 
The second classification was to identify whether or not any of the transcripts in a 
locus were likely to be protein coding or not. If any transcript making up a locus 
 
Figure 22. IGV visualization of novel locus XLOC_054452. This plot from the 
Integrative Genomics Viewer [1] exhibits an example of a novel locus and the novel 
transcripts making up that novel locus. Each row of the plot is a different gtf 
transcriptome assembly. The first one is the Final LGRC assembly as specified in 
Chapter 4, section 7. The second row is showing the union gtf assembly of UCSC, 
Ensembl 64, and Vega gene, and in this area of the human genome, there are no 
annotated transcripts in those assemblies. The next line shows the AceView 
assembly. We do not find the same structure in this region of AceView, however, we 
did identify some of the same exons as found in AceView. The next two lines show 
that there is some evidence from the Broad catalogue that a lincRNA originates from 
here, though only one of the exons matches up with our assembly, and no transcripts 
of uncertain coding potential. Finally, the yellow box shows the information contained 
in the gtf file, specifically the locus id, chromosomal locations, the class code (“u” for 
unknown”) and whether or not this transcript overlaps with AceView and the Broad 
catalogue (and this accurately reflects what we observe visually).  
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was identified as having coding potential, we classified the locus as having 
protein coding potential. Otherwise, loci were classified as non-coding. To 
classify whether novel transcript was coding or non-coding, I used the Coding 
Potential Assessment Tool (CPAT) to classify transcripts into coding or non-
coding [138]. I selected this tool over other tools such as PhyloCSF [139] 
because this tool specifically does not use multi fasta alignments and sequence 
conservation to separate coding and non-coding loci. This is because non-coding 
RNAs, specifically lncRNAs are generally less conserved, so using conserved 
sites to distinguish is not ideal, and because an entirely sequenced based 
method runs significantly faster than other methods. CPAT uses a logistic model 
composed of four variables: longest ORF size identified in the transcript, ORF 
coverage (ratio of the ORF to the length total transcript sequence), the Fickett 
TESTCODE statistic, and hexamer usage biases. The logistic model is trained on 
three items, the set of coding transcripts, the coding sequences within those 
coding transcripts, and a set of non-coding transcripts. Once the model is trained, 
I did a sanity check by supplying it with the Broad LincRNA transcripts and the 
Broad Transcripts of Uncertain Coding Potential. Nearly all of the LincRNA 
transcripts did not meet the cutoff for coding potential, and were thus classified 
as non-coding and a large amount of the TUCPs were classified as having 
coding potential. I then supplied my novel transcripts to see which ones were 
likely to have high coding potential, and used the recommended coding 
probability cutoff of > 0.4 to classify a transcript as coding and < 0.3 to classify it 
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as coding. Any transcripts falling inbetween were classified as undetermined (the 
CPAT group recommends using CP >= 0.364 as being coding). I also modified 
the CPAT code so that it would return the longest ORF sequence so that other 
downstream analysis of these novel transcripts would be easier. 
 
Overall, a novel locus was classified as being coding if it had at least one 
transcript classified as coding, otherwise it was classified as non-coding. By this 
criteria, there are 191 coding loci and 1,664 non-coding loci identified in the final 
chronic lung disease transcriptome assembly. 
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5. IDENTIFYING CHRONIC LUNG DISEASE ASSOCIATED 
DIFFERENTIALLY EXPRESSED AND DIFFERENTIALLY SPLICED 
NOVEL LOCI 
5.1. Introduction 
5.1.1. Expanding to a larger set of LGRC samples to better explore the 
chronic lung disease transcriptome and find novel disease-associated loci 
for downstream validation 
In this section, like in the previous Chapter, we’ll be utilizing a larger set of lung 
tissue samples from the LGRC. The introduction of the Illumina HiSeq 2000 
[140,141] gave our group the ability to go from sequencing 8  samples with 20-40 
million reads in a week to sequencing 32 samples in a week with 40-60 million 
paired end reads per sample. Assembling a lung tissue transcriptome from >200 
samples is far more likely to identify more lowly, but consistently expressed 
regions, than using the < 90 samples we originally started with. After developing 
and improving a set of steps in Chapter 4 for assembling the chronic lung 
transcriptome assembly in a data driven manner, our goal in this chapter is to 
identify the best novel candidates to push towards future experimental validation 
by our functional genomics group. Updating our methodology, we will identify 
novel loci that are differentially associated with either COPD/emphysema or IPF, 
and from this, we can move the pulmonary field forward towards not just 
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examining regions of expression that are well annotated but also those that can 
now be discovered by fully utilizing next generation RNA-sequencing. 
 
5.1.2. Moving from continuous models to discrete negative binomial 
models 
While one could argue that with a sufficiently large number of observation, and 
by filtering out cases where most of the data is zero or close to zero as we’ve 
done, a transformed set of discrete values can be fitted with statistical model as 
with large enough counts or enough observations, by the central limit theorem 
they are likely to approach behave somewhat normally [142]. However, in this 
section, I’ve pushed towards using a set of negative binomial generalized linear 
models to model statistical differences, and these are much better suited for 
untransformed count data, specifically counting reads that align to genes and 
transcripts of interest [143]. The main applications I’ve utilized in this chapter are 
edgeR (Empirical analysis of Digital Gene Expression in R) [144], an expansion 
of the limma package [145], and DEXSeq [104], an expansion of the DESeq 
package [146], but used to look at differential exon/feature usage within a 
locus/gene.  
 
The edgeR package uses a negative binomial model of the read counts, library 
sizes, and relative abundance of a gene and then calculates the dispersion (aka 
a more general term than variance, which is the dispersion in normal, continuous 
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data) using maximum likelihood, and allows the user to supply multiple variables 
to correct before testing for the final condition [144]. The DEXSeq package also 
uses generalized linear models with a negative binomial distribution, however, 
like my work in chapter 3, use a model that includes an interaction term 
comparing expression counts of exons in a locus with condition [104], and this is 
why I can also modify this package to look at splice junctions in a locus 
compared to condition, however, unlike my method, they also share information 
between genes to calculate a better estimate of the dispersion that is part of the 
negative binomial model. In the next section, I use both of these methods to 
calculate differential locus expression, differential exon usage, and differential 
splice junction usage associated with chronic lung disease to attempt to identify 
novel loci that could play a role in these diseases.  
 
3.1.3. Novel loci could play a role in chronic lung disease 
By working with newer high throughput methodologies such as next generation 
RNA-sequence, our understanding what and how much of the genome is 
encoded into functional RNA has expanded and changed, and it is suspected 
that there is a lot more to what is transcribed than just the annotated protein 
coding genes [147-149]. Recent work using RNA-sequencing datasets such as 
the Illumina Human Body Map data has led to the discovery of one type of novel 
regions of expression called long non-coding RNA (lncRNA) and a specific 
subtype called long intergenic non-coding RNA (lincRNA) [66]. These lncRNAs 
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have been shown to play different roles including in epigenetics [150], 
transcription regulation [151,152], and post-transcriptional regulation including 
splicing [153] and the translation machinery (one example that is relevant is that 
RNA-RoR is a p53 repressor), [154]. Another example of a newer understanding 
of what can be found in the transcriptome has been the identification that more 
and more transcribed RNAs thought to be non-coding RNAs actually have short 
ORFs that encode for small peptides [155-157]. These are just a few examples of 
recent changes in understanding of the transcriptome, and they illustrate why 
there are limitations in understanding if we only use hybridization-based methods 
or only use RNA-seq to look at the gene expression of what is already known 
[158]. We could potentially be missing key regulators that could play a very real 
role in disease, and these newer, more novel non-coding and coding loci have 
been shown to play such a role [159,160]. 
 
Novel non-coding RNAs have been shown to play a role in disease progression 
in cancer. PCAT-1, a previously unannotated lincRNA, was specifically identified 
as a repressor and could be use to stratify patient into prostate cancer subtypes 
[124]. PCA3 is another non-coding RNA that has been shown to play a functional 
role in prostate-cancer cell survival [161]. Long non-coding RNAs have also been 
shown to play roles in response to stress [162] as well as other diseases 
[163,164] including neurodegenerative diseases such as Alzheimer's [165], 
fragile X syndrome[166], and other cancers such as breast cancer [167,168].  
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Based on the above work using RNA-seq to discover new functional RNAs that 
contribute to disease [169], and based on the fact that I’ve identified nearly 2,000 
novel loci in the previous chapter, it is my hypothesis, that if some of these are 
differentially expressed or differentially spliced in chronic lung disease 
(specifically IPF or COPD with emphysema), that future functional analysis of 
those novel candidates could improve our understanding of these diseases and 
may open up new avenues of research in IPF and COPD. 
 
5.2. Results 
5.2.1. Sample study design and setup 
All lung samples were acquired from the Lung Tissue Research Consortium 
(LTRC) and utilized by the Lung Genomics Research Consortium, both 
supported by the National Heart, Lung, and Blood Institute (NHLBI). Patient 
clinical information, pulmonary functions, demographics, imaging results and 
pathology and clinical diagnoses were available and can be found at the LGRC 
web portal [lung-genomics.org]. After removing lower quality sequences, 
duplicate samples, and samples missing some specific demographic data 
(smoking status) used in the generalized linear models, we were left with a set of 
224 COPD, ILD, and control lung tissue samples (Table 11).  
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Since we’ve been focusing on analysis COPD with emphysema and  IPF 
samples, we subset the 224 samples down into those more specific phenotypes 
based on clinical demographic data set by the LGRC. COPD with emphysema 
were the samples diagnosed with COPD that had percent emphysema greater 
than 25% and the IPF samples were the samples that had a major diagnosis of 
ILD and a minor diagnosis of UIP/IPF. Unlike in Chapter 2 and 3, these 129 
samples (Table 12) were not as clearly matched for other demographic data, so 
when doing further analysis, we will include more demographic variables. All 
studies were approved by the Institiutional review Boards at participating 
institutions and per LTRC protocol all patients signed informed consent. 
 
Table 10: Demographics of the 224 lung tissue samples 
 ILD COPD Control 
# of samples 85 103 36 
Age 61.3 ± 10.8 64.0 ± 10.4 63.1 ± 11.8 
Sex 51 M, 34 F 59 M, 44 F 21 M, 15 F 
Race 
77 CAU, 1 HIS,  
3 AFA, 2 NAM,  
1 OTH (1) 
100 CAU, 3 AFA 34 CAU, 2 AFA 
Smoking status 
2 Current, 
59 Former,  
24 Never 
2 Current,  
97 Former,  
4 Never 
1 Current,  
24 Former,  
11 Never 
Pack years 25 ± 19 (24) 54 ± 36 (4) 37 ± 35 (11) 
% DLCO 46 ± 18 (9) 56 ± 23 (15) 81 ± 16 (4) 
FEV1% predicted 72.1 ± 17.5 (64) 56.6 ± 26.1 (15) 98.3 ± 8.3 (12) 
% emphysema 1.3 ± 2.4 (41) 18.7 ± 19.5 (12) 0.6 ± 1.0 (15) 
 (No duplicate subjects and all have smoking status) 
 (Numbers in parenthesis are missing demographic values) 
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5.2.2. Differential expression of novel loci in chronic lung disease 
Using the assembly annotation from Chapter 4, first we filtered out out lowly 
expressed loci using the mixture model. If a loci was not expressed in at least 
25% of the samples across the two conditions (disease versus control), beinc 
compared, then it was filtered out of the analysis. Next, after correcting for 
singleplex/multiplex, smoking status, age, and sex, we identified both the known 
and novel loci that were significantly differentially expressed between IPF and 
control subjects and between emphysema versus control subjects at a q value < 
0.01. Within the IPF versus control results, there were a total of 120 novel loci 
that were differentially expressed at a q < 0.01 (Figure 23). Furthermore, within 
Table 11: Demographics of the IPF and emphysema samples subset from ILD 
and COPD samples, respectively 
 
IPF 
COPD w/ 
Emphysema 
Control 
# of samples 62 31 36 
Age 63.9 ± 9.1 56.9 ± 9.2 63.1 ± 11.8 
Sex 44 M, 18 F 17 M, 14 F 21 M, 15 F 
Race 
57 CAU, 1 AFA, 2 
NAM, 1 OTH (1) 
30 CAU, 1 AFA 34 CAU, 2 AFA 
Smoking status 
45 Former, 
17 Never 
30 Former, 
1 Never 
1 Current, 
24 Former, 
11 Never 
Pack years 25 ± 18 (17) 51 ± 36 (1) 27 ± 23 (5) 
% DLCO 42 ± 17 (7) 37 ± 11 (8) 82 ± 16 (4) 
FEV1% predicted 73.1 ± 18.9 (46) 28.6 ± 10.9 (7) 98.3 ± 8.3 (12) 
% emphysema 1.4 ± 2.3 (31) 43.0 ± 11.8 0.6 ± 1.0 (15) 
 (Numbers in parenthesis are missing demographic values) 
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the emphysema results there were 10 novel loci that were differentially 
expressed at the same cutoff (Figure 24).  
 
Following the reasoning of Chapter 2 and 3, we examined which novel loci were 
concordantly associated with both chronic lung diseases. We identified that 4 out 
of the 10 novel loci that were differentially expressed in emphysema versus 
control (q < 0.01) were also differentially expressed in IPF versus control (q < 
0.01). Their locus ids were XLOC_007946, XLOC_009327, XLOC_018132, and 
XLOC_054452. All four of these loci were not predicted to be coding, so it looks 
like concordantly differentially expressed novel loci between the two genes are 
potentially more likely to be novel non-coding RNAs rather than novel protein 
coding RNAs. However, with such a small number identified, this is not 
conclusive. An example of one of these loci, XLOC_054452, shows very 
significant changes expression differences between chronic lung disease 
samples and control samples (Figure 25). 
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Figure 23. Differentially expressed (q < 0.01) known and novel loci in IPF versus 
control. (a) A smear plot displays the behavior of all the differentially expressed 
genes in IPF versus control. The black squares are loci that are not DE. The smaller 
red squares are DE known loci; they overlap features from UCSC, Ensembl, or Vega 
annotations. The green circles highlight the location of differentially expressed non-
coding novel loci, the blue and purple circles highlight the novel single exon and >1 
exon, respectively, that are predicted by CPAT to be protein coding. (b) A heatmap of 
the 120 novel loci shows how the individual genes behave in the samples. The 
columns are samples (black being the IPF samples, white are controls), and the rows 
are the genes z-score normalized to center around zero. On the left side, the purple 
bars highlight the novel loci that are likely to be protein coding. 
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Figure 24. Differentially expressed (q < 0.01) known and novel loci in 
emphysema versus control. (a) A smear plot displays the behavior of all the 
differentially expressed genes in emphysema versus control. The black squares are 
loci that are not DE. The smaller red squares are DE known loci. The green circles 
highlight the 7 differentially expressed non-coding novel loci and the blue circle 
highlights the single DE protein coding novel loci in emphysema. (b) A heatmap of 
the 10 novel loci shows how the individual genes behave in the samples. The 
columns are samples (black being the emphysema samples, white are controls), and 
the rows are the genes z-score normalized to center around zero. On the left side, 
the purple bars highlight the novel locus that is likely to be protein coding. 
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5.2.3. Differential splicing of novel loci in chronic lung disease 
In this section, we’ve moved from using normal linear models, as was done in 
Chapter 3, to utilizing more appropriate negative binomial generalized linear 
models in order to identify alternative splicing. Furthermore, instead of just 
 
Figure 25. XLOC_054452 is one of four concordantly differentially expressed 
non-coding novel loci shared by IPF and emphysema. This plot from the 
Integrative Genomics Viewer [1] displays the significant difference in expression of 
this novel non-coding locus. The locus is very up-regulated in the control samples as 
seen in the blue plot showing coverage of reads from the control samples piled up 
compared to the red and black wiggle plots in the next two rows representing IPF and 
emphysema samples. We also highlight that there is some overlap of this locus with 
AceView and the Broad catalogue, however, the structures we see here better match 
the expression in this region than the AceView or Broad annotations.  
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looking at the behavior of reads that overlap splice junctions, we’ve also 
expanded to examine exon behavior as well. A locus that has both differentially 
spliced junctions and differentially spliced exons is likely to be a better candidate 
for downstream functional validation studies.  
 
Within the novel 1,885 novel loci in the final assembly, we’ve identified 70 loci 
with IPF-associated alternative exon usage (q < 0.25) and 8 loci with 
emphysema-associated  alternative exon usage. There were 478 significant 
exons within the 70 significant loci in IPF and 24 significant exons within the 8 
significant loci in emphysema, based on the DEXSeq negative binomial model.  
 
A similar model looking at splice junction usage was used to look within the 70 
and 8 loci with differentially associated exon usage in IPF and emphysema, 
respectively, to see if there was evidence that splice junctions were also 
demonstrating alternative splicing behavior (Table 13). Only IPF associated 
novel loci appear to have both differential exon and splicing usage 
simultaneously. We’ve consistently seen that the signal is clearer in IPF in 
previous sections, so it is not surprising that this remains the case.  
102 
 
 
 
 
The novel loci that show differential exon and differential splicing usage are the 
main candidates for future functional validation, though unfortunately there are no 
concordant examples of novel loci being alternatively spliced in both IPF and 
emphysema. An example of an IPF-specific case of splicing is visualized in 
Figure 26. This example shows switching in expression between two exons.  
 
 
 
Figure 26. DEXSeq visualization of novel locus XLOC_019951 shows that it is 
differentially spliced in IPF versus control samples.  
Table 12: Novel loci differential splicing results 
 
IPF versus 
Control 
COPD w/ 
Emphysema 
versus Control 
Novel loci with differential 
exon usage (q < 0.25) 
70 8 
Subset of the above novel 
loci that also had differential 
splice junction usage (p < 
0.05) 
8 0 
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5.3. Discussion 
 
The aim of this chapter was to illustrate the potential value inherent in 
reassembling the lung disease transcriptome and identifying 1,855 novel non-
coding and potentially coding loci. By identifying there were 120 IPF-associated 
and 10 emphysema-associated differentially expressed (q < 0.01) novel loci, 4 of 
which were concordantly expressed between the two non-malignant chronic lung 
diseases, I’ve shown that there is merit to moving beyond known gene 
expression and using RNA-seq to explore what is unannotated in the 
transcriptome.  
 
In this chapter we also utilized more appropriate models to identify changes in 
digital gene expression as well as potential changes in splicing in the novel loci. 
One thing we have identified is that generally the novel loci are not the most 
highly expressed loci in the transcriptome. This isn’t surprising given that 
potential reasons for their lack of clear annotation in other transcript assemblies 
is likely due to their either being lung specific and/or due to their having moderate 
average expression in the lung tissue samples. As with our previous work in IPF 
and COPD, generally the signal is much, much higher in IPF samples compared 
to the COPD with emphysema samples, more than an order of magnitude when 
considering the number of significantly differentially expressed novel loci. While 
the novel loci are generally balanced between upregulated and downregulated 
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behavior in IPF, 7 of the 10 loci were downregulated in IPF. This could be an 
artifact of such having only 10 DE novel loci, but at the same time, it could 
highlight that it is easier to find genes that are upregulated in the control samples 
because of the heterogeneity and noise in the emphysema samples.  
 
By using all of the information and classification of the novel loci gleamed in this 
and the previous chapter, we are able to better categorize which of the novel loci 
to target for further studies. As our focus has been on concordant changes 
between IPF and COPD, the identification of 4 novel non-coding loci, some with 
very obvious expression differences between cases and controls (Figure 25), will 
be our highest priorities. Following this, we plan to prioritize the coding and non-
coding novel loci by selecting those with the highest fold changes and average 
expression differences between conditions as shown in the smear plots.  
 
In this chapter we also explored the feasibility of identifying potential disease 
associated alternative splicing, however, unlike when we explored known 
isoforms in Chapter 3, we were unable to identify concordant changes in 
alternative splicing in novel loci between both diseases. This could be due to the 
differences between the diseases, or that the novel loci are not as likely to be 
influenced by shared changes between the two chronic lung diseases. We were 
able to identify significant alternative splicing of novel loci in IPF and will 
preferentially examine those because within a subset we could see both changes 
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in exon and splice junctions in the same locus. Overall, the fact that we could 
identify and classify novel loci and explore changes in gene expression and 
alternative demonstrates the flexibility and power of next generation RNA-
sequencing. 
 
By sequencing the RNA from a much larger number of patients than in previous 
chapters, we were able to benefit from an ever high resolution detailed look into 
non-malignant chronic lung disease transcriptome and could begin to identify 
categories of disease associated novel loci. The identification of these novel 
targets makes possible further downstream functional analysis that could identify 
better targets for therapy and lead to an even better understanding of chronic 
lung disease pathogenesis. 
 
5.4. Methods 
5.4.1. Library Preparation and Sequencing  
A final set of 281 LGRC lung tissue samples were processed (this includes the 
87 samples from Chapter 2. The clinical and demographics information for all of 
these samples was obtained from the LGRC data portal [lung-genomics.org]. All 
of these samples were processed with non-stranded polyA-based Illumina 
protocols. 
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The library preparation on the first 95 samples was done using Illumina’s mRNA 
Sequencing Sample Preparation kit starting with 1 μg of total RNA as discussed 
in Chapter 2, section 4.2. These samples were run single plex (1 sample per lane 
of a flow cell) on GAIIx, generating an average of 20-40 million 75bp paired end 
reads per sample.  
 
For the latter 186 samples, library preparation was done using Illumina’s TruSeq 
RNA sequencing sample preparation kit starting with 200-500 nanograms of total 
RNA from each sample. The mRNA was isolated using poly(A) selection, 
fragmented for a specific time to get a range of fragments lengths centered 
around 200 bp, and randomly primed for reverse transcription followed by first 
and  second-strand synthesis to create double-stranded cDNA fragments. Ends 
were repaired, ligated to a unique barcoded index paired end adapter (4 unique 
indices used for 4 samples per lane multiplexing). These fragments were PCR 
amplified, purified, and then subjected to cluster generation on a cBot machine 
[170] using Illumina TruSeq Paired-End Cluster Generation Kits. Next, the 
samples were multiplex sequenced on a HiSeq machine (4 samples per lane, 8 
lanes per flow cell). Around 40-60 million 99 bp paired end reads having an 
average inner distance between mate pairs of 0 to -25 bp (25 bp overlap).  
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5.4.2. RNA-Seq Data Processing and Sample Selection 
Initial data processing was done using the GAIIx and HiSeq pipeline for their 
respective samples. Reads from each flow cell lane were demultiplexed (if 
required) and fastq files were generated. Fastq files were initially aligned 
following the Tophat methodology laid out in Chapter 4, section 2, and sample 
quality was performed per the specifications in Chapter 4, section 3. Final Tophat 
alignments were performed following the methodology developed in Chapter 4, 
section 4. After quality control, 237 LGRC samples remained for further analysis. 
Data analysis from this point on was completed using R version 2.15.1 [171] and 
Bioconductor 2.11 [172].  
 
5.4.3. Obtaining gene, exon, and splice junction counts for known and 
novel loci 
The final Tophat alignments (bam files) and the final filtered chronic lung disease 
transcriptome annotation (gtf file) composed of and 370,228 assembled 
transcripts making up 26,631 loci (1,855 of which were novel loci) were used to 
obtain gene-level, exon-level, and splice junction-level reads counts. Within the 
237 good quality LGRC samples, 6 were duplicate runs of the same lung tissue 
sample (average values were used for these samples), and seven samples were 
missing smoking status (a variable that was required to have no missing values 
for the statistical modeling analysis). Once the above samples were removed, 
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224 samples remained. These were utilized in the downstream analysis to 
identify chronic lung disease associated differences from control samples.  
 
Gene-level counts: To obtain gene level counts for each locus per LGRC sample, 
the HTSeq python program htseq-count was used [146,173]. The htseq-count 
program currently requires that the alignment files in binary format (bam) be 
converted to text based alignments (sam) and sorted by read names rather than 
by chromosomal coordinates (which is the standard way the sam/bam files are 
sorted by Tophat). The number of reads aligned to each locus are counted and 
overlapped reads are handled using the “intersection-strict” mode from HTSeq. 
Here is an example of how htseq-count was run: 
 htseq-count \ 
-m intersection-strict \ # Mode to deal with ambiguous reads 
-s no \ # Specifies that reads are not stranded 
-t exon \ # Feature type from gtf file  
-i gene_id \ # id from gtf file used to unify transcripts 
sample.sam \ 
final.assembly.gtf > sample.gene.counts.txt 
 
Exon-level counts: To obtain exon level counts for each of the exons making up 
each locus per LGRC sample, two python programs supplied with the DEXSeq 
exon differential exon expression program were employed [104]. This program 
similarly uses the HTSeq framework [173]. The dexseq_prepare_annotation.py 
program identifies all non-overlapping exonic parts (based on each locus) in the 
supplied GTF annotation (our final chronic lung disease transcriptome 
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annotation). The dexseq_count.py program uses the alignment files (in sam 
format) and the output gtf from dexseq_prepare_annotation.py in order to count 
the number reads aligned to exons. See the DEXSeq Bioconductor manual for 
more information 
(http://bioconductor.org/packages/2.11/bioc/vignettes/DEXSeq/inst/doc/DEXSeq.
pdf). Since the protocol used for the RNA-seq samples was unstranded, some 
single exon transcripts in the final assembly do not have a specified 
strandedness, so I had to modify the python code to handle this. Here is an 
example of how dexseq_count.py was run:  
python2.6  dexseq_count.py \\ 
-p yes \ # Specifies that the data is paired end 
-s no \ # Specifies that the data is not stranded 
aligned.file.sam \ 
output.exon.counts.txt 
  
Splice junction counts: Tophat supplies junction.bed files that contain the counts 
of reads that span each reported splice junction for each lung tissue sample 
aligned. Normalized splice junction values (number of reads spanning a splice 
junction / number of reads spanning all splice junctions in a sample) were used to 
filter out splice junctions expressed too lowly (1 RPM or less).  
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5.4.4. Locus filtering using a mixture model of gene-level normalized count 
data 
Loci were defined as “signal” or “noise/zero” using a mixture model in a similar 
fashion to Chapter 2, section 2.4. The mixture model utilized the log normalized 
read count data per gene from HTSeq (log(reads per locus/total number of reads 
in a sample)). For a locus to be included in the differential expression analysis, it 
had to be classified as “signal/reliably expressed” in at least 25% of samples out 
of the two phenotypic groups (COPD with emphysema, IPF, or Control) being 
compared.  
 
5.4.5. Differential expression analysis of known and novel loci 
Differentially expressed loci were identified using the edgeR package [144]. The 
edgeR package utilizes negative binomial generalized linear models to fit to the 
gene-level count data. The following negative binomial model was utilized: 
 
Countsi ~ 
βintercept + βexperiment.plexXexperiment.plex + βsmoking.statusXsmoking.status  +  βageXage 
+  βsexXsex  +  βdisease.statusXdisease.status  +  εi 
 
In this model, the counts of the ith gene were used. The library size and 
dispersion estimates of the counts were estimated and used to normalize the 
counts per model. The counts were then corrected for plex (whether or not the 
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sequencing protocol for a specific sample was a singleplex or multiplex protocol; 
this had one of the larger effects on counts), smoking status (current, former, 
never), age, and sex. The final variable was the disease status (chronic lung 
disease {IPF or COPD/emphysema] versus control). Loci whose counts were 
differentially expressed based on the disease status variable were then identified. 
The p values returned from this were corrected using FDR [174].  
 
Within the significantly differentially expressed loci, a list of novel loci were 
identified (see Chapter 4, section 9). These loci were then classified into whether 
or not they were single exon loci and whether or not they had coding potential 
(Chapter 4, section 10). 
 
5.4.6. Differential exon and splice junction analysis of novel loci 
In this step, we specifically examined only the novel loci to identify if any of these 
novel loci were differentially spliced. We looked for differential splicing by first 
identifying differentially expressed exons within a given loci and then identifying if 
differential splice junction usage occurred as well. Candidates with both 
differential exons and differential junctions were considered the strongest 
candidates of being alternatively spliced with disease. 
 
Disease-associated differentially expressed exons per novel loci were identified 
using the DEXSeq package [104]. Similar to edgeR the DEXSeq package utilizes 
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a negative binomial generalized linear model, however, it looks at the 
multiplicative interaction effect between conditions being compared and the 
exons within a locus. The following negative binomial model was utilized: 
 
Exon-Countsipq ~ 
 βintercept + βexperiment.plexXexperiment.plex  +  βsmoking.statusXsmoking.status  +  βsexXsex 
+ βexonXexon  +   βdisease.statusXdisease.status  +  βinteraction(Xexon*Xdisease) + εi 
 
In this model, the normalized exon counts of the ith splice junction for gene p in 
patient sample q were used. The library size and dispersion estimates of the 
counts were estimated and used to normalize the counts per exon per model. 
The counts were then corrected for plex (whether or not the sequencing protocol 
for a specific sample was a singleplex or multiplex protocol; this had one of the 
larger effects on counts), smoking status (current, former, never), and sex. In the 
current version of DEXSeq, only categorical variables are available, so age was 
unable to be modeled. There were then two terms for exon and disease 
condition, respectively, followed by an interaction term between exon and 
disease condition. Using the DEXSeq methodology, novel loci with exons that 
were significant for the last term were identified (Note that for all of the samples 
involved, this method can take a very long time to run, up to many days).  
 
Similarly, we identified novel loci with disease-associated splice junction counts 
using the DEXSeq package [104]. This method is an update of the method used 
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in Chapter 3 for finding differential splice junction usage, in that it is more correct 
to use a negative binomial model when the independent variable consists of 
discrete counts rather than continuous expression measurements. The following 
negative binomial model was used to identify differential splice junction usage: 
 
Splice-Junction-Countsipq ~ 
 βintercept + βexperiment.plexXexperiment.plex  +  βsmoking.statusXsmoking.status +  βsexXsex 
+ βexonXexon  +   βdisease.statusXdisease.status  +  βinteraction(Xexon*Xdisease) + εi 
 
In that model, the splice junction counts of the ith splice junction for gene p in 
patient sample q was used. These counts are normalized within the DEXSeq 
model by using the splice junction library size (or total number of splice junction 
counts per sample). As in the exon model, counts were corrected for plex 
(whether or not the sequencing protocol for a specific sample was a singleplex or 
multiplex protocol; this had one of the larger effects on counts), smoking status 
(current, former, never), and sex (and not age). This was followed by two terms 
for splice junction and disease condition, respectively. The last variable of the 
model is the multiplicative interaction term between the different splice junctions 
of a locus and the sample disease conditions. Using this DEXSeq methodology, 
we were able to identify novel loci with differential splice junction usage. 
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To identify the best candidate loci with the most evidence of disease-associated 
differential splicing, we identified the subset of genes that had both significant 
changes in exons as well as splice junctions. 
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6. CONCLUSIONS, LIMITATIONS, AND NEXT STEPS 
Improvements in next generation high throughput RNA-sequencing have given 
us the ability to advance our understanding of the transcriptome by allowing us to 
interrogate RNA transcripts without needing an a priori understanding of their 
exact structure and location. We’ve employed these improved technologies to a 
set of lung tissue samples from the LGRC in order to gain new insights into the 
non-malignant ILD/IPF and COPD/emphysema chronic lung disease 
transcriptome. Some key insights that were ascertained in this work include: 
 
 The known lung transcriptome landscape was defined using a mixture 
model to separate lowly expressed genes from reliably expressed genes, 
and compared to other specimens from other human organs, lung tissue 
had the largest transcriptomic potential by having the largest number of 
genes reliably expressed 
 Within a lung tissue sample in the LGRC, about half of the known genes 
are reliably expressed and the other half are noise or not measured, and 
across all of the samples about 1/3rd of the known genes are never reliably 
expressed, 1/3rd are variably expressed, and 1/3rd are always reliably 
expressed. 
 The genes that were always reliably expressed across lung tissue 
samples with varying phenotypes generally showed a large overlap 
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between conditions and similar KEGG pathway were enriched regardless 
of phenotype 
 By using the reads that overlapped splice junctions, significant disease 
associated differential splicing was identified. When examining concordant 
alternative splicing between IPF and COPD with emphysema, PDGFA and 
NUMB were identified and validated. PDGFA was further validated as 
alternatively spliced in an independent set of more heterogeneous COPD 
samples and NUMB was validated in an independent set of ILD samples. 
IPF-specific alternatively spliced SCEL was also validated in both the 
initial and independent set of ILD samples versus control samples. 
 Developed and improved a pipeline to assemble a data driven transcript 
and utilized improvements such as: removing spurious single sample 
splice junctions, lowly expressed and poor quality transcripts, and 
simplifying the final assembly 
 Identified 1,855 novel loci in the assembled chronic lung disease 
transcriptome and classified these loci based on number of exons and 
coding potential 
 Displaying the worth of moving beyond known gene expression and 
exploring the unannotated parts of the transcript because after doing this 
120 novel differentially expressed loci associated with IPF and 10 novel 
differentially expressed loci associated COPD with emphysema were 
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identified. Four of these novel non-coding loci are concordantly 
differentially expressed in both diseases 
 Showed that alternative splicing could also play a role in IPF by identifying 
novel loci that had both differential exon usage and differential splice 
junction usage  
 Categorized the novel loci into those that are most likely to lead to 
interesting new functional research in IPF and COPD by identifying the 
novel loci with the highest average expression and concordant fold 
changes in disease such as loci XLOC_054452. 
 
This work shows the significance of pushing the pulmonary field forward towards 
using these newer sequencing technologies, especially considering that further 
experimentation on these previously undetected chronic lung disease-associated 
novel loci and alternative splicing could lead to new therapeutic targets and both 
a wider and deeper understanding of what is happening in these two chronic lung 
diseases. 
 
Despite the benefits of this work, this study does have a number of limitations 
that could be addressed with future studies. Despite being able to identify shared 
alternative splicing of known genes and shared differentially expressed novel 
loci, many more features tend to be identified as significant in the IPF samples. 
This may be due to a more homogeneous cell population in IPF, different 
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collection methods, or the variable alveolar destruction in emphysema (which is 
not necessarily well accounted for by a single measurement of percent 
emphysema). Moreover, control samples were collected from the histologically 
normal lungs of patients who had lung cancer. These factors should not 
confound the analysis presented in this study when focused on convergent 
emphysema and IPF biology, but could be an issue when looking at results within 
individual disease. Lung tissue samples are also heterogeneous when it comes 
to cell type, so future studies could mitigate this step by using single cell 
sequencing techniques or by studying these two diseases in regions that have 
more homogeneous cell population such as looking at airway epithelium. An 
additional limitation of this study comes from the heterogeneity of disease 
location within the lung. An example of this is that while we have a general 
measure of emphysema across the lung (% emphysema), the amount of 
emphysema varies across the lung tissue, so a single sample is inadequate 
when accounting for this localization heterogeneity. Another area of difficulty is 
understanding how differences in isoforms change function, as, unlike gene 
expression, there are no databases or gene sets for isoform-level function as 
there is with gene-level function. Despite the above limitations, next steps for this 
work include validating more differential spliced genes, validating the changes in 
expression in the novel loci associated with chronic lung disease, and exploring 
the genomic functions of these novel loci in the lung. 
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